Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges

Miguel Olivas-Aguirre 1, Liliana Torres-López 1, Kathya Villatoro-Gómez 1, Sonia Mayra Perez-Tapia 2, Igor Pottosin 1,∗ and Oxana Dobrovinskaya 1,∗

1 Laboratory of Immunobiology and Ionic Transport Regulation, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colima 28045, Mexico; miguel.a.olivas@gmail.com (M.O.-A.); torres_liliana@ucol.mx (L.T.-L.); kathya8899@hotmail.com (K.V.-G.)
2 Unidad de Desarrollo e Investigación en Bioterapeúticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (ENCB-IPN), Mexico City 11340, Mexico; mayra.perez@udibi.com.mx
* Correspondence: pottosin@ucol.mx (I.P.); oxana@ucol.mx (O.D.)

Abstract: Cannabidiol (CBD), a major non-psychoactive component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD’s interaction with conventional anticancer drugs; (d) CBD’s potential in palliative care for cancer patients; (e) CBD’s tolerability and reported side effects; (f) CBD delivery for anticancer treatment.

Keywords: anticancer activity; anticancer treatment; adverse effects; cannabidiol; clinical trials; drug delivery; palliative care; pre-clinical studies; synergism

1. Introduction

Cannabidiol (CBD) is the most abundant natural cannabinoid found in cannabis plants. The advantage of CBD is the apparent lack of any intoxicating effect. CBD has been proposed for the treatment of pain, insomnia, several psychological conditions, graft-versus-host disease, inflammatory diseases, and cancer [1–7]. The wide spectrum of biological effects seems to be related to numerous molecular targets for CBD, which include various G-protein-coupled receptors, ion channels and ionotropic receptors, transporter proteins, nuclear receptors, and numerous enzymes involved in lipid, xenobiotic/drug, and mitochondrial metabolism [7,8]. The anticancer properties of CBD are mostly reported in studies in vitro, and to a lesser extent in vivo, whereas clinical studies including cancer patients are still scarce. The goal of the present review is a critical assessment of CBD’s potential for anticancer therapy, recent advances, and challenges.

2. CBD Shows Anticancer Properties in Pre-Clinical Studies In Vitro and In Vivo

In the last several years, there has been growing interest in the use of cannabinoids in the treatment of various types of cancer. Two of them, CBD and ∆9-tetrahydrocannabinol (THC), have demonstrated pronounced anticancer activity in pre-clinical in vitro and in vivo trials. Because the use of THC in chemotherapy is limited due to its psychotropic effects, special attention is paid to the non-psychoactive CBD, which also has demonstrated a greater antitumor effect than THC [9–11]. A recent comprehensive review summarizes the biological effects of CBD in different tumor types and is highly recommendable for interested readers [6]. The biological effects of CBD have been tested in a broad range of tumor cells in vitro and in vivo (Table A1 in Appendix A), including glioma/glioblastoma [9,11–19], breast
cancer [9,20–26], prostate carcinoma [9,27–29], leukemia/lymphoma cells [9,10,25,30–33],
gastric cancer [9,34,35], colon/rectal cancer [9,36–38], lung cancer [39–41], cervical
cancer [25,39,42]), neuroblastoma [43,44], medulloblastoma [45], ependymoma [45],
pancreatic cancer [46,47], ovarian cancer [28], endometrial cancer [48], bladder urothelial
carcinoma [49], and head and neck squamous cell carcinoma [50].

Anticancer drug candidates are initially screened on cell lines, to reveal their biological
effects and underlying molecular mechanisms. The antitumoral activity of CBD was tested
in vitro in a wide range of concentrations, from 0.01 to 100 µM (Table A1). However, the
variation in culture conditions (passage number, medium composition, presence of serum
and cellular confluence) and the mode of CBD administration (single or repetitive daily
administration) hinder direct data comparison and assessment of the relative sensitivity
of cell lines to CBD. Lymphoblastic leukemia, particularly of T lineage, presents higher
sensitivity to CBD when compared to myeloid leukemia and breast and cervical cancer, as
was demonstrated in comparative viability assays carried out under the same experimental
conditions [25]. To understand the antitumor action of CBD, it is necessary to consider the
sequence of events induced in target cells and their interrelation. Table A1 summarizes
control targets and processes in different cancer models affected by CBD at the time range
from minutes to days, whereas a synthetic timeline for CBD’s biological effects, related to
its antitumor activity, is given in Figure 1.

![Figure 1](image-url)

**Figure 1.** Time course of CBD-triggered changes in cellular processes in experimental cancer models
in vitro. Increased activity is shown in green, whereas decreased activity is shown in pink.

There are only a few studies that monitored the earliest/instantaneous responses
to CBD. A rapid rise in the cytosolic free calcium (Ca²⁺) level ([Ca²⁺]ᵣ), which occurs
within the first 3–5 min after CBD administration, was observed in breast cancer [9] and
leukemic T cells [25]. In the latter work, concurrent measurements of mitochondrial Ca²⁺
([Ca²⁺]ₘ) and [Ca²⁺], revealed that the [Ca²⁺] rise was preceded by [Ca²⁺]ₘ transience,
indicating the early involvement of mitochondria in the process [25]. Accordingly, the rapid
dissipation of mitochondrial membrane potential (ΔΨm) and cytochrome C (Cyt C) release
from mitochondria to cytosol was observed in this model during the first 10–20 min [25].

At physiological conditions, mitochondria are major contributors to reactive oxygen
species (ROS) production. They also possess an efficient antioxidant enzyme system for
rapid ROS scavenging, to prevent cell damage. Accordingly, mitochondrial disturbances
are related to the increased production of ROS and oxidative stress [51]. Augmented
ROS levels were reported from the first hour of CBD administration in different models,
such as murine thymoma [33], human breast cancer [9], and T cell leukemia [25], and
could be detected also at longer (24–96 h) times of observation (Table A1). Increased ROS
production seems to be an important mediator of CBD cytoxicity. ROS scavengers α-
tocopherol (αTOC) and N-acetylcysteine (NAC) counteracted the antiproliferative effects
of CBD in human glioblastoma [11,12], breast cancer [9,21], T cell leukemia [31], and mouse
medulloblastoma [45]. Accordingly, αTOC rescued cancer cells from apoptosis [15,18,22,31].
Since mitochondrial damage causes reduced ATP production, the energy-consuming basic cellular functions such as migration are affected by CBD. Decreased migration capacities were reported from the first hour of CBD treatment in glioblastoma [13] and leukemia [25] and during 24–48 h of observation in multiple cancer types such as bladder carcinoma [49], neuro- and glioblastoma [17,41,43], breast [20,21], cervical [39], lung [39], and endometrial cancer [48], and squamous cell carcinoma [50].

Among early events, which developed within minutes after CBD administration, decreased levels of active (phosphorylated) AKT were reported [44], which in turn can be related to the inhibition of cellular metabolism and proliferation. Inhibition of AKT/mTOR and upregulation of MAPK signaling pathways were confirmed in many models (Table A1, Figure 1). Since decreased p-AKT levels are a key signal for the activation of autophagy [52] and are related to the upregulation of MAPK p38 [18], p-AKT downregulation is maintained over time [16,18,19,22,32] and correlates with the rise in p-p38 [18,19,39], decrement in p-mTOR [32], upregulation of key autophagic genes [16], and induction of autophagy [25,44]. Autophagy, depending on its scale, moderate or large, may act as a protective mechanism or can eventually lead to cell death [52].

In many cell types, CBD predominantly evoked apoptosis, as was evidenced by an increase in the expression/function of pro-apoptotic initiators (Bad, tBid) and pore-forming proteins (BAX), a decrease in antiapoptotic Bcl-2 [16,22], Cyt C release [14,22,25,31,34], and the activation of caspases [9,14,22,25,31,35,37]. Of note, in many studies, the type of cell death was not specified because only metabolic assays were performed. Thus, apoptosis likely is not a unique process induced by CBD but can be paralleled and/or affected by concurrent processes such as autophagy and metabolic inhibition. For example, although apoptosis was triggered first by CBD in leukemic cells, severe mitochondria damage and oxidative stress caused the switch to the mitochondrial permeability transition pore (mPTP)-driven necrosis [25].

There is plenty of evidence that CBD can strike multiple cellular targets. CBD possesses low affinity for classical cannabinoid receptors CB1 and CB2 but can efficiently antagonize their agonists; it also acts as a CB2 inverse agonist. Meanwhile, many of the CBD-mediated cellular effects are independent of the endocannabinoid system receptors. CBD acts as an antagonist of G-protein-coupled receptor GPR55, and as an agonist for serotonin receptor 5HT and transient receptor potential vanilloid receptors/channels TRPV1 and TRPV2 [2,6,7,53]. In addition, CBD is a small and lipophilic molecule. Thus, it easily permeates the plasma membrane, being able to reach intracellular targets as well. Accordingly, the mitochondrial outer membrane voltage-dependent anion channel (VDAC) was reported as a highly relevant CBD target [25,54]. Therefore, CBD should be considered as a multitarget agent, capable of triggering various scenarios, depending on the cellular and microenvironmental context, which includes a characteristic pattern of CBD-binding receptors, cellular metabolic state, CBD concentration, and bioavailability.

The involvement of CB1/CB2 receptors was addressed in several cancer models (Table A1). Specific antagonists of CB1 receptors or CB1 receptor knockdown abolished the antiproliferative effects of CBD in a colorectal cancer cell line [36]. Both CB1 and CB2 receptors were shown to be involved in the development of different processes induced by CBD, including autophagy in human neuroblastoma [44], proliferation and viability decrease in breast cancer [9], apoptosis in glioblastoma [18] and colon carcinoma [27], and reversed invasiveness of human cervical and lung cancer cell lines [39,40]. The involvement of CB2 but not CB1 in CBD-triggered effects was demonstrated in several models: the inhibition of proliferation and viability in murine thymoma and human leukemic cells [31] and human glioblastoma [12] and PARP cleavage in prostate carcinoma [27].

On the other hand, U87 and U373 human glioma cell lines [12,13] and glioma stem-like cells [16] express CB1 and CB2 but the antiproliferative effect of CBD was insensitive to the respective antagonists SR141716 and SR144528. CBD decreased the cell viability of D425 and D283 medulloblastoma and IC-1425EPN and DKFZ-EP1NS ependymoma cell lines, independent of CB1, even though human medulloblastomas and ependymomas express
CB1 and CB2 [45]. CBD (5 μM) decreased the survival of the MDA-MB-231 breast cancer cell line in a CB1/CB2-independent manner [22], although the antiproliferative effect was partially CB2-dependent when CBD was added at a higher concentration (10 μM) [9].

The antitumor effects of CBD were shown to depend on TRPV1 in human neuroblastoma [44], cervical, lung, and breast cancer [39,40], and colon adenocarcinoma [36], but not in glioblastoma [12,13], human leukemia, or murine thymoma [31]. The CBD-dependent decrease in the viability of glioma stem-like cells was dependent on both TRPV1 and TRPV2 [16]. High expression of TRPV2 in drug-resistant cancers such as triple-negative breast or advanced non-small cell lung cancers is correlated with better prognosis, and the activation of TRPV2 by CBD assists drug (doxorubicin)-induced apoptosis in breast cancer cells or provokes apoptosis by CBD itself in lung cancer cells [55,56]. Reported results should be interpreted with caution, due to the different culture conditions, CBD concentrations, or mode of CBD application. For example, viability and proliferation in the MDA-MB-231 cell line (breast cancer) was reported to be independent of TRPV1, when cells were cultured in serum-free conditions [22]. A contradictory result was obtained in another study, where the same cellular model was used, but CBD was added daily in a similar concentration and cells were cultured with serum [9].

It should also be noted here that, in most works on the dependence of CBD-triggered processes on plasma membrane receptors, only late (12–48 h) events were studied (Table A1). For instance, CBD (5 μM, serum-free medium) produced multiple cytotoxic effects in Jurkat cells at 24 h, which were CB2-dependent [31]. Contrary to this, applied to the same cell model, CBD (30 μM, with serum) provoked almost instantaneous [Ca^{2+}]i and [Ca^{2+}]m rises and induced cell death, which were independent of CB1/CB2 and GPR55, but dependent on the direct modulation of the mitochondrial VDAC, [Ca^{2+}]m overload, and mitochondrial damage [25]. Although CBD-dependent ROS production has been confirmed in numerous cancer models, and CBD cytotoxicity is suggested to be related to oxidative stress, the question of the dependence of ROS production on any kind of plasma membrane receptors has not yet been addressed.

Proliferator-activated receptor γ (PPARγ) in peroxisomes appears to be an additional intracellular target for CBD. The antiproliferative effects of CBD (10 μM) in colon cancer cells were counteracted by PPARγ antagonist GW9662 [36].

An important issue is the selectivity of the drug for cancer vs. healthy tissues. Several pre-clinical studies demonstrated that the concentrations of CBD that were cytotoxic in cancer cell lines did not significantly decrease the viability of healthy cells such as primary glioblastoma (up to 50 μM CBD) [14], human oral keratinocyte cell line (up to 15 μM for 24 h) [50], human keratinocytes, rat preadipocytes and mouse monocyte–macrophage cell lines (10 μM for 72 h) [9], murine bone marrow stromal cells, and resting but not activated human CD4^+ lymphocytes (30 μM for 24 h) [25]. The MCF-10A mammary epithelial cell line was more resistant to CBD than the MDA-MB-231 breast cancer cell line (up to 10 μM for 24 h) [22]. In some cases, apoptosis mediated by CBD (16 μM) occurred earlier in cancer (EL-4 murine thymoma, 1 h) than in healthy tissue (thymocytes, 6 h) [33].

Although, in general, healthy tissue cells seem to be less sensitive to CBD cytotoxicity, some of their functional properties may be affected. Murine splenocytes stimulated for cytokine production showed lower production of IL-2, IL-4, and IFN-γ after being pretreated with CBD [57–59]. On the other hand, the functionality could be restored later. For example, human resting CD4^+ cells, pretreated with CBD (30 μM, 24 h), completely restored their ability to be activated after 72 h in CBD-free conditions [25].

The anticancer properties of CBD were confirmed in experiments in vivo. CBD reduced tumor growth and metastasis in animal models such as human xenografts of squamous carcinoma [50], colorectal and gastric cancer [35,37], lung cancer [39,40], prostate carcinoma [29], glioma [12], and neuroblastoma [43], as well as orthotopic implants in mice, such as medulloblastoma/ependymoma [48], breast cancer [21,23], and leukemia [31]. Working CBD doses were within 1–100 mg/kg body weight, typically 5 mg/kg [9,39,40,50], which is roughly equivalent to a low micromolar range. Administration of CBD daily or
every 3 days caused a significant reduction of tumor volume and a strong reduction in metastatic spread to other organs, as well as the induction of apoptosis [31], inhibition of EGF/EGFR signaling [23], and activation of caspase 3 [43].

3. Synergism: CBD Improves the Effect of Conventional Anticancer Therapy

Synergistic effects of cannabinoids with other compounds were observed and discussed in early studies during the late 1990s, suggesting that CBD and other molecules such as terpenoids from Cannabis sativa can boost the activity of other compounds such as THC. This effect was denominated as the entourage effect; however, the evaluation of the synergistic effect of CBD with other drugs was mainly restricted to research on neurological diseases [60, 61]. Eventually, the synergistic potential of CBD in other pathologies, including cancer, gained interest and became a subject of ongoing research.

Combined chemotherapy is the main therapeutic anticancer strategy that potentially reduces drug resistance. Accordingly, the search for the best drug combination is paramount. In this regard, the synergism of CBD with several cytotoxic drugs, including THC and conventional chemotherapeutics such as gemcitabine, cytarabine (ARA-C), cyclophosphamide (CPA), cisplatin (CIS), paclitaxel, temozolomide, carbustine, vincristine (VIN), carfilzomib, and erastin, as well as irradiation, was observed (Table 1) [10, 11, 15, 45, 62–70]. The synergistic effect was manifested either by an increase in cytotoxicity in vitro or by a decrease in tumor size in xenograft models. In multiple studies, the synergistic effect was quantitatively analyzed by the evaluation of the so-called Combination Index (CI), which has to be <1 in the case of synergy for a two-drug combination [71]. For a combination of CBD with different anticancer drugs, CI ranging from 0.22 to 0.9 was reported (Table 1).

In several cases, the combined effect of CBD with anticancer agents was non-trivial. In the study by Deng and colleagues [66], CBD itself exhibited pronounced cytotoxicity against several glioblastoma cell lines (with IC50 = 3.2 µM). However, synergism was demonstrated only when low CBD concentrations were combined with DNA-damaging agents, but not with the most of other drugs, where the effect of drug combinations was only additive or even antagonistic [66]. Another study demonstrated that CBD synergistically enhanced the cytotoxic effects of CPA in different MDB cell lines, but only at high concentrations, whereas low CBD concentrations (<5 µM) antagonistically interfered with the CPA activity [45]. Tamoxifen (TAM) was shown to interact synergistically with CBD in the suppression of T-ALL cells and this synergism was higher when cells were pretreated with TAM or both drugs were added simultaneously compared to the case of TAM after CBD. This was explained by the fact that TAM pretreatment prevented the mitochondrial permeation transition pore formation by binding to cyclophilin D, so that a consequent CBD application resulted in a permanent mitochondrial Ca2+ overload and more severe mitochondrial dysfunction [72].

The outcome of CBD interactions depends on the cancer type/phenotype and microenvironmental conditions. For example, non-identical interactions of CBD with other cytotoxic drugs (e.g., CPA, THC) were observed in two medulloblastoma cell lines: synergism in D283 and antagonism in PER547. Remarkably, the synergism observed in D283 in vitro was not confirmed in the xenograft environment [45]. Similarly, CBD acted synergistically with ARA-C in myeloid leukemia cells but not in acute lymphoblastic leukemia [10]. Another issue is the nature of the companion anticancer agent. In myeloid leukemia, CBD exhibited synergistic effects with ARA-C, but antagonism with VIN [10].

Thus, the possible outcome of CBD interaction with any of the conventional chemotherapeutic agents should be carefully examined in its context, which includes the experimental model, the cancer phenotype, the nature and the concentration of the drug, as well as individual patients’ particularities.
| Cancer Type        | Experimental Model          | Chemotherapeutics Employed                     | Combination Index (CI) | Synergistic Effects | Proposed Mechanism          | References |
|-------------------|----------------------------|------------------------------------------------|------------------------|---------------------|-----------------------------|------------|
| Bladder cancer    | Cell lines: T24            | Gemcitabine (0–20 µM)                           | ND                     | ↑ Cytotoxicity      | ND                          | [62]       |
|                   |                            | Cisplatin (0–100 µM)                           |                        |                     |                             |            |
|                   |                            | CBD (0–30 µM)                                  |                        |                     |                             |            |
| Breast cancer     | Cell lines: MCF-7, MDA-MB-231 | Doxorubicin (0–20 µM)       | MDA-MB-231 0.59–0.83, MCF-7: 0.54–0.63 | ↑ Cytotoxicity | ND                          | [63]       |
|                   |                            | Paclitaxel (0–500 nM)                          |                        |                     |                             |            |
|                   |                            | CBD (0–20 µM)                                  |                        |                     |                             |            |
| Breast cancer     | Xenograft:                 | Paclitaxel (2.5–35 µM)                          | MDA-MB-231: 4T1: 0.6–0.4, 4T1: 0.9–0.8 | ↑ Cytotoxicity | 5HT1A receptors            | [64]       |
|                   | MDA-MB-231, 4T1            | CBD (2.7–4 µM)                                |                        |                     |                             |            |
| Glioma            | Xenograft: U87MG           | Temozolomide (5 mg/kg)                          | 0.78–0.887             | ↓ Tumor volume      | Autophagy-mediated cell death | [11]       |
|                   |                            | CBD (3.7 mg/kg)                                |                        | ↓ Tumor weight      |                             |            |
| Glioma            | Cell lines: U87MG, MZC     | Doxorubicin (0–200 nM)                         | ND                     | ↑ Cytotoxicity      | TRPV2 overexpression        | [65]       |
|                   |                            | Temozolomide (0–400 µM)                        |                        |                     | TRPV2 activation            |            |
|                   |                            | Carmustine (0–200 µM)                         |                        |                     |                             |            |
|                   |                            | CBD (10 µM)                                    |                        |                     |                             |            |
| Glioma            | Cell lines: T98G, U251, U87MG, | Temozolomide (1–1000 µM)           | ND                     | ↓ Proliferation      | ↑ Cytotoxicity              | [66]       |
|                   |                            | Carmustine (3–1000 µM)                        |                        |                     |                             |            |
|                   |                            | Cisplatin (0–1000 µM)                          |                        |                     |                             |            |
|                   |                            | CBD (1–10 µM)                                  |                        |                     |                             |            |
| Leukemia          | Cell lines: CCFR-CEM, HL60 | Cytarabine (5.4 µM)                            | CCFR:CEM: 0.92–0.61, HL60: 0.43–0.034 | ↑ Cytotoxicity | ND                          | [10]       |
|                   |                             | Vincristine (1.9 nM)                           |                        |                     |                             |            |
|                   |                             | CBD (4 µM)                                     |                        |                     |                             |            |
| Medulloblastoma-Ependymoma | Cell lines: D283, D425, PER547 | Cyclophosphamide (0–20 µM) | ND                     | ↑ Cytotoxicity      | Cell cycle arrest            | [45]       |
|                   |                             | CBD (0–7 µM)                                   |                        |                     | ↑ Apoptosis                 |            |
| Multiple myeloma  | Cell lines: U266, RPMI8226 | Carfilzomib (0–100 nM)                        | Specified as CI < 1    | ↑ Cytotoxicity      | Apoptosis induction         | [69]       |
|                   |                             | CBD (12.5 µM)                                  |                        |                     |                             |            |
Table 1. Cont.

| Cancer Type     | Experimental Model                          | Chemotherapeutics Employed                  | Combination Index (CI) | Synergistic Effects                                      | Proposed Mechanism                        | References |
|-----------------|---------------------------------------------|---------------------------------------------|------------------------|----------------------------------------------------------|-------------------------------------------|------------|
| Glioma          | Cell lines: U87MG                           | THC (0–3.5 μM) CBD (0–3.5 μM)               | ND                     | ↑ Cytotoxicity ▼ Tumor volume ▼ Tumor weight              | Autophagy-mediated cell death             | [11]       |
|                 | Xenograft: U87MG                           |                                             |                        |                                                          |                                           |            |
|                 |                                             | Erastin (2.5–10 μM) Piperazine erastin      | GSC387: 0.64 GSC387: 0.53 GSC3832: 0.52 | ↑ ROS ▼ Tumor cell ▼ Invasion                           | ROS-mediated SLC7A11 upregulation         | [68]       |
|                 |                                             | (10 μM) CBD (0–10 μM)                       |                        |                                                          |                                           |            |
|                 |                                             |                                             |                        |                                                          |                                           |            |
|                 |                                             | THC (0–5.4 μM) CBD (0–1.4 μM)               | SF126: 0.22 U251: 0.29–0.27 | ▼ Cell growth ↑ Caspase activation ↑ Apoptosis           | ERK inhibition                            | [15]       |
|                 |                                             |                                             |                        |                                                          |                                           |            |
|                 |                                             | CBD (0–20 μM) Irradiation (0–5 Gy)          | U87MG: 0.9–0.08 T98G: 0.9–0.8 GL261: 0.9 | ↑ Cytotoxicity ↑ Autophagy ▼ Tumor volume ▼ Tumor progression | MAPK signaling                           | [70]       |
|                 |                                             |                                             |                        |                                                          |                                           |            |
| Leukemia        | Cell lines: CCFR-CEM, HL60                  | THC (0–50 μM) CBD (0–50 μM)                 | CCFR-CEM: 0.53–0.44 HL60: 0.34–0.29 | ↑ Cytotoxicity                                          | ND                                        | [10]       |
| Multiple myeloma| Cell lines: U266, RPMI8226                  | THC (12.5–50 μM) CBD (0–50 μM)              | Specified as C < 1    | ↑ Cytotoxicity                                          | Cell cycle arrest Autophagic cell death   | [69]       |
| Medulloblastoma | Cell lines: D283, PER547                    | THC (0–10.5 μM) CBD (0–9.5 μM)              | ND                     | ↑ Cytotoxicity ▼ Cell cycle arrest ▼ Autophagy           | ROS-dependent mediated autophagy and apoptosis | [45]       |
| Ependymoma      |                                             |                                             |                        |                                                          |                                           |            |
4. CBD in Palliative Care

Standard anticancer treatments such as chemotherapy, radiotherapy, hormone therapy, and nutritional adaptations are known to impact negatively on the patients’ life quality by disrupting sleep and appetite, producing pain, increasing the appearance of mood disorders, and generating immunosuppression, anemia, fatigue, and multisystemic toxicity, especially with intensive or long-term protocols. In this context, there is a great deal of interest in palliative care [73]. Despite the general popularity of the topic, there is only a limited number of published studies regarding the palliative properties of cannabinoids, which present significant methodological flaws. We will discuss some of these reports in more detail.

More than 3000 cancer patients using medical cannabis were monitored for 2 years in Israel to assess its safety and efficacy [74]. Of these patients, 66% reported a substantial improvement in their health condition and life quality from the first month of use. Despite the fact that the obtained results are encouraging, several limitations complicate their interpretation: (1) the medicament formulation was not of pharmaceutical purity grade and represented whole plant oil extract or inflorescence, including flowers, capsules, or cigarettes; (2) data from all patients were combined and analyzed regardless of patient age, cancer type, and stage. In another study from the Mayo Clinic published recently, patients, including cancer patients, used THC and CBD as a palliative agent against pain, appetite loss, and insomnia [75]. In the majority (71%) of patients using CBD, these symptoms were alleviated. However, there were many uncontrolled variables in the CBD consumption, including concentrations (not reported), frequency of consumption (daily, weekly, or rarely), and methods of administration (vape, spraying, pills, topical application). In the majority of trials so far, instead of pure CBD, CBD/THC formulations with different ratios and purity were employed.

It is worth mentioning here that the consumer demand for CBD products has increased drastically during the last decade [76]. As a result of this rising demand, numerous CBD-containing products have appeared for online purchase. In a recently published study, eighty-four CBD products from 31 companies were analyzed for whole-spectrum cannabinoid content (CBD, THC, cannabinoisin, cannabigerol, among others) using high-performance liquid chromatography [77]. CBD concentrations varied significantly, from 0.10 to 655 mg/mL, with only 31% of accurately labeled products. The rest of the products were either underlabeled (43%) or overlabeled (26%). Mislabeling occurred frequently in vaporization liquids. Importantly, THC was detected in 20% of samples, sometimes in concentrations sufficient to provoke intoxication. These findings indicate the urgency of manufacturing control and testing standards, to prevent inappropriate use. In this context, double-blind, placebo-controlled, randomized clinical trials to assess the use, efficacy, and safety of CBD in palliative care are now being conducted [4, 78].

4.1. CBD in Chemotherapy-Induced Pain

It is estimated that around 70–90% of patients with advanced cancer experience pain during therapy due to the therapy-induced damage in the peripheral nerves. There is an extensive search for strategies to limit the development of chemotherapy-induced neuropathic pain (CINP) or to relieve pain, in order to improve patients’ life quality [74, 79, 80].

CBD has been demonstrated to exert analgesic effects in a murine model of CIS-induced allodynia [81]. Similar effects were also observed in cancer patients, followed for up to 6 months of CBD consumption, with a significant reduction in pain caused by chemotherapy. Most of the patients (67%) stopped using analgesics or reduced the dosage [74].

There are at least 76 clinical trials, either completed or recruiting, which evaluate the benefits of CBD in pain management. Among them, 17% are focused on the analgesic properties of CBD in cancer patients (www.clinicaltrials.gov, accessed on 14 February 2022). Such trials employ CBD either alone or in combination with other cannabinoids in doses ranging from 2.5 mg to 40 mg, mostly via an oromucosal spray. Low (<25 mg) doses of
CBD provoked analgesia, while higher doses caused no analgesia but secondary effects [82]. Patients with terminal cancer-related pain and refractory to opioids experienced a decrease in pain severity within the first few weeks of CBD/THC consumption [83,84]. Similar results were obtained in another trial, in which more than 30% of patients reported a reduction in baseline pain [83]. Contrary to these findings, several independent double-blind, placebo-controlled phase 3 trials showed no significant difference between CBD/THC and placebo effects on pain management, although patients reported some improvement in their life quality (NCT01361607; NCT01424566) [85,86].

Based on data from in vitro and clinical trials, several mechanisms have been proposed for CBD-mediated analgesia, which includes the action through different cell membrane receptors, ion channels, transporters, as well as intracellular enzyme targets [8]. However, there are only a few studies on tumor models. Accordingly, in a breast cancer xenograft, CBD (2.5–10 mg/kg) prevented the manifestations of CINP induced by paclitaxel, acting through the serotonin receptor 5TH1A [64]. Importantly, CBD treatment also displayed a synergism with paclitaxel against breast cancer cells [64]. In another work, CBD (0.625–20 mg/kg) was shown to attenuate CINP, induced by paclitaxel or oxaliplatin, but not by vincristine [87]. Additional experiments are still needed to confirm the analgesic effects of CBD on chemotherapy-induced neuropathic pain and to reveal the underlying mechanisms.

4.2. CBD for Healthy Cells’ Protection

Several anticancer agents are toxic to healthy cells, especially when the drugs are accumulated in certain organs. For example, it is well known that CIS promotes acute renal failure (ARF) in a dose-dependent manner in approximately one third of patients [88,89]. CIS is differentially absorbed by the medullar and cortical sections of the kidney, inducing apoptosis and necrosis in these tissues. Several mechanisms have been implicated in CIS-mediated nephrotoxicity; thus, drugs limiting such mechanisms have emerged as renoprotective agents [90]. In an ARF mice model, the pre-administration of CBD (10 mg/kg/day) significantly attenuated the renal damage induced by CIS [89]. Additionally, CBD has been shown to potentiate CIS activity in different cancer types [62,66]. Thus, CBD may be considered as a promising renoprotector against CIS-induced renal failure.

Another effective chemotherapeutic drug, DOX, may provoke cardiotoxicity when accumulated. For cancer patients with DOX-developed cardiomyopathy, the prognosis is poor [91,92]. In mice with DOX-induced cardiomyopathy, CBD (10 mg/kg/administered i.p. for 5 days) reduced the markers of ARF and cardiac injury [93]. The effects of CBD as a cardioprotector were attributed to a reduction in oxidative/nutritive stress and cell death and it improved the mitochondrial function and biogenesis. From a therapeutic point of view, CBD usage in cancer patients under regimens including DOX is encouraged, considering that CBD also potentiates the cytotoxic effects of DOX (Table 1), allowing the adjustment of DOX doses and limiting its cardiotoxicity.

4.3. CBD against Opportunistic Infections

Cancer patients undergoing chemotherapy are at high risk for opportunistic infections. It is estimated that 30% of cancer patients with non-hematological tumors and up to 85% of patients with acute leukemia develop life-threatening infections. Some chemotherapeutics such as CPA cause immunosuppression by altering hematopoiesis, affecting the total white blood cell count and generating neutropenia [45,94,95]. Chemotherapy, surgical, or diagnostic procedures can also disrupt anatomic barriers in the process of infection. To overcome these complications, the concurrent use of antimicrobial agents and growth factors to restore hematopoiesis is being considered [96].

In this regard, the ability of CBD to influence hematopoiesis was observed. For example, in orthotopic mouse models of ependymoma and medulloblastoma, CBD (50 mg/kg/p.o.) was able to reverse hematopoietic toxicity caused by CPA treatment, as measured by an increase in leukocyte and neutrophils counts. However, the survival rate of animals in
this model was not improved, despite the fact that, in experiments on medulloblastoma and ependymoma cell lines performed in vitro, CBD enhanced the cytotoxic effects of CPA (Table 1) [45]. Notably, an increase in the total number of white blood cells, lymphocytes, monocytes, and neutrophils was also seen in cannabis consumers [97]

Several studies evidenced the marked antimicrobial activity of CBD. In particular, CBD was effective against various species of Gram-positive bacteria, including *Staphylococcus* spp., *Listeria* spp., *Enterococcus* spp., and *Bacillus* spp., with the range of minimum inhibitory concentrations (MIC) being 1–4 µg/mL [98–102]. CBD also potentiated the effect of bacitracin [101]. Importantly, it was highly efficient against many Gram-positive resistant strains [102]. Although the majority of Gram-negative species are significantly less sensitive to CBD (MIC > 60 µg/mL), some “urgent threat” pathogens such as *Neisenna honrorhoeae*, *Neisenna meningitides*, and *Legionella pneumophilia* showed high sensitivity, with MIC around 1 µg/mL [102]. In addition to its bactericidal properties, CBD protects the mucous membrane and limits the susceptibility to infections due to its antioxidative, anti-inflammatory, and vasodilatory properties [103–106].

4.4. CBD in Anorexia-Cachexia Syndrome

Up to 80% of cancer patients undergo a wasting syndrome, characterized by vomiting, anorexia, asthenia, and anemia [107,108]. The resulting cancer cachexia (CCA), together with immunosuppression, increases their susceptibility to infections, limits chemotherapy’s effectiveness, and increases the risk of eventual organ failure. Therefore, cancer patients are strongly encouraged to adopt strategies that promote appetite increase, weight gain, and immunity recovery. Advanced cancer patients treated with CBD (2.5 mg p.o.) or CBD/THC blends showed improved appetite compared to the placebo group [84]. Another controlled study confirmed weight gain in cancer patients receiving CBD of pharmaceutical grade (20 mg/daily/p.o.) [109]. Interventional phase 2/1 clinical trials have been proposed in order to evaluate the effects of CBD in emesis, cachexia, and appetite alterations by estimating the body mass index, nausea, taste alteration, energy intake, and lean body mass in cancer patients under chemotherapy (NCT03245658; NCT04585841; NCT04482244; NCT02675842).

Collectively, available data suggest that CBD can improve the life quality of cancer patients under chemotherapy (Figure 2) and call for further extended clinical trials of CBD as a potential palliative care agent.

![Figure 2. CBD can improve side effects of anticancer chemotherapy.](image-url)
5. Evidence of Anticancer Activity of CBD from Clinical Trials and Case Reports

Although numerous pre-clinical studies have demonstrated the anticancer activity of CBD (Sections 2 and 3), objective clinical evidence is still very scarce. A comprehensive review of pre-clinical and clinical reports concerning the anticancer activity of cannabinoids, including CBD, was performed and published recently [110]. In this work, the data available in the PubMed and EBSCO databases, congress presentations, books, and clinical trials registered at ClinicalTrials.gov website were analyzed. Among them, 77 publications of case reports with various types of cancers were revealed and classified as weak (81%), moderate (5%), or strong (14%). Accordingly, the cases were considered as strong or moderate when they met the following criteria: (a) patients presented an active form of cancer at the time of cannabinoid application and (b) clinically validated laboratory documentation about clinical response and improvement was available. In strong cases, cannabinoids were utilized without a concurrent therapy, whereas in moderate cases, anticancer therapies were executed in parallel. In our opinion, the latter combined approach is more pertinent than CBD monotherapy. In clinical trials reported by Kenyon and colleagues, pharmaceutical-grade synthetic CBD (STI Pharmaceuticals) was tested on 119 patients with advanced cancer of different types, including breast, prostate, and colorectal cancers, non-Hodgkin’s lymphoma, and glioblastoma [109]. Patients were given 10–30 mg of CBD (depending on tumor mass), twice per day (“three days on/three days off” basis). Favorable clinical responses were observed in 92% of patients, evidenced by a reduction in tumor size (repeated scans) and a decrease in circulating tumor cells. Positive dynamics were observed in patients treated with CBD both alone and in combination with a standard therapy [109]. Importantly, the authors reported the case of a glioma patient where the improvement was observed only by taking synthetic CBD of pharmaceutical grade, but not cannabis oil extract [109]. It should be noted here that clinical researchers, physicians, and the FDA expressed their concern that many patients use a variety of cannabis oils or whole plant extracts of questionable quality (not of pharmaceutical grade) in self-prescribed dosages, which may be ineffective or even harmful for patients [109,111].

Thus, the following important issues should be addressed in the path toward the use of medical CBD for cancer patients: (1) CBD formulations and administration methods to reach the desirable cytotoxic effect specifically in the cancer tissue or favorable effects in palliative care; (2) possible side effects for specific CBD formulations and concentrations administrated by any specific route.

6. CBD Tolerability, Toxicity, and Adverse Effects

CBD’s toxicity against numerous cancer cell lines has been identified, as previously discussed (Section 2). Although healthy cells have been reported to be less sensitive, the causes and mechanisms of the differential sensitivity of cancer and healthy cells to CBD toxicity are still unclear. Moreover, CBD may target a variety of surface and intracellular molecules (receptors, ion channels/transporters, enzymes) and triggers multiple signaling pathways present in both cancer and healthy cells. Taken together, these facts raise safety and side effect issues. According to traditional protocols, drug toxicity is first tested in pre-clinical animal models. Pre-clinical studies, carried out on animal models, reported acute and chronic adverse effects of CBD on different organs and systems (Table A2) [112–122]. There are several highly recommended comprehensive reviews, which critically analyzed the CBD safety and toxicity experiments carried out in animal pre-clinical and human clinical trials [53,123–127]. The following important observations should be mentioned: (1) regarding the administration route, in most human trials, CBD was administrated orally or by inhalation, whereas predominantly intraperitoneal (i.p.) and intravenous (i.v.) injections and sometimes the oral route were used in animals; (2) CBD pharmacokinetics and molecular targets seem to differ between humans and rodents; these differences should be taken into consideration when extrapolating results obtained in pre-clinical models to humans; (3) regarding the composition, in numerous CBD toxicity reports in humans, patients consumed not pure CBD but different preparations of CBD of unknown
concentration and uncertain composition. Many preparations marketed as CBD contain also variable quantities of THC [77]. Since the toxicity profile and side effects caused by THC and CBD are different and THC seems to be more toxic [126], the data obtained in these studies are misleading, reporting the net effect of THC, CBD, and their interaction. Drug–drug interactions represent a very important issue in the case of CBD, because it targets enzymes implicated in drug metabolism and excretion [8]. Thus, it may prolong the presence and increase the toxicity of co-administrated drugs. Taking all the aforementioned factors into consideration, we will restrict ourselves to the most prominent and reliable data concerning the toxicity and adverse effects of CBD.

Obviously, CBD’s tolerability depends on the doses, frequency, routes of administration, and treatment duration. CBD is usually well tolerated during acute and short-lasting treatment in moderate doses. At a range of 3–30 mg/kg (i.p.) or 0.1–30 mg/kg (i.v.), CBD did not change the heart rate, blood pressure, gastrointestinal (GI) transit, respiration, biochemical blood parameters, and hematocrit in rodents [53]. In piglets, CBD doses of 10 mg/kg (i.v.) were well tolerated, whereas higher doses (50 mg/kg) in some cases caused hypotension and cardiac arrest [116,125]. In rhesus monkeys, high CBD doses of 150–300 mg/kg (i.v.) caused acute CNS toxicity (tremor, sedation, and prostration) within 30 min of injection, whereas prolonged treatment for 9 days elicited bradycardia, hypopnea, cardiac failure, liver weight increase, and inhibition of spermatogenesis [113,125]. For the same model (rhesus monkeys), chronic oral CBD application (30–300 mg/kg/day, 90 days) caused systemic negative effects on the liver, heart, kidneys, and thyroids, and inhibited spermatogenesis [113,124,125]. Negative effects of chronic CBD on embryonic development were reported in rats when relatively high doses (75–250 mg/kg/day) were administrated orally during pregnancy, which included developmental toxicity, decreased fetal body weight, increased fetal structural variations, and embryofetal mortality [125].

Clinical reports in humans are scarce, and, obviously, are limited to low and moderate doses. No disturbances in physiological parameters or psychomotor functions were observed in clinical CBD trials after oral administration (15–160 mg), i.v. injection (5–30 mg), or inhalation (0.15 mg/kg) [53]. No side effects were observed during the prolonged CBD treatment of cancer patients (up to 60 mg daily, orally, up to 6 months) [109].

Most of the reliable clinical trials (i.e., double-blind, randomized, placebo-controlled) were performed on patients (children and adults) suffering from treatment-resistant epilepsy or schizophrenia, or related neurologic and psychotic disorders. The CBD dose range utilized in these trials was usually from 0.5 to 50 mg/kg/day or from 200 to 1000 mg/day for psychiatric studies. When CBD was administrated orally (25–50 mg/kg/day) for an extended period (weeks), moderate adverse effects included somnolence and fatigue, sleep disorders, diarrhea and GI intolerance, and respiratory complications, and pneumonia, thrombocytopenia, and liver and blood abnormalities were reported [125,128–131]. Pyrexia was relatively common in children with Dravet’s or Lennox-Gastaut syndrome during 3- or 4-week treatment trials with doses of 5–20 mg/kg/day administrated orally [125,128,129].

Since CBD is suggested to be included in combined anticancer chemotherapy protocols, CBD’s hepatotoxicity, which can cause changes in drug metabolism, is an issue of special importance. A hepatotoxic effect was documented in pre-clinical and clinical studies when relatively high CBD doses were administrated for a prolonged time [53,123–127]. As was revealed by a randomized, double-blind trial that included 171 patients, hepatocellular injury represents the most frequent adverse effect, so it was recommended to test serum transaminases and total bilirubin levels in all patients prior to starting the treatment with Epidiolex®, which is CBD in an oral solution [132,133]. Importantly, CBD targets the cytochrome P450 system and is metabolized by CYP3A4 and CYP2C1 in human liver microsomes (HLMs), giving rise to 6α-OH-, 6β-OH-, 7-OH-, and 4”-OH-CBDs [134]. A female patient, treated for 6 years with tamoxifen, and, additionally, by CBD, which inhibited CYP3A4/5 and CYP2D6, presented a consequent reduction in N-desmethyltamoxifen and active metabolite endoxifen [135]. In cancer patients, especially if they have liver diseases
or a poor metabolic profile, possible effects of CBD on cytochromes P450, which in turn can affect the pharmacokinetics of conventional anticancer drugs, need to be considered.

7. Concerning Better CBD Delivery for Cancer Therapy

Satisfactory delivery of anticancer therapeuticals should provide its efficient accumulation in the target cancer tissue, with minimal side systemic effects on other organs. CBD is a highly lipophilic compound, which is poorly soluble in aqueous solutions and highly sensitive to light, temperature, and oxidation, which underlies its relatively low bioavailability [136]. CBD, when administrated orally, can precipitate in the GI tract, resulting in poor GI permeability. It undergoes then the first step of metabolism by liver and gut enzymes and is predominantly excreted through the kidneys [136,137]. As a result of the first step of metabolism, the oral CBD bioavailability is estimated to be between 5% and 19% [136,137]. Variable pharmacokinetics profiles were reported, depending on the means of CBD administration. These include more traditional and better-studied oral/mucosal, inhalation, and smoking, and less explored intravenous routes [138].

7.1. Free CBD Delivery

To date, the only CBD formulation approved by the FDA for the treatment of rare forms of epilepsy is Epidiolex®, CBD in an oral solution (100 mg/mL), with maximum recommended doses of 20 mg/kg/daily. Currently, there are numerous clinical trials of CBD for the treatment of different disorders, including palliative care in cancers, where CBD is delivered predominantly as an oil solution, orally, or via inhalations (https://clinicaltrials.gov/ct2/results?cond=&term=cannabidiol&cntry=&state=&city=&dist=, accessed on 14 February 2022).

As was discussed in Section 2, a relatively broad range of CBD concentrations was tested in studies in vitro to prove its anticancer properties. Significant variations in experimental models and culture conditions complicated a comparative analysis. Considering cell cultures supplemented with serum as a better approximation of physiological conditions, effective concentrations were in the µM range. When CBD was administrated orally in humans (20 mg), its maximal plasma concentration achieved at 3 h was in the range of 7.9–19.1 ng/mL (i.e., 5–15 nM), with better bioavailability in women (Table 2) [139]. A novel self-emulsifying drug delivery system (SEDDS) was proposed recently to improve the oral CBD bioavailability. This resulted in 2–4-fold higher plasma CBD concentrations when compared to oral/mucosal administration, with a lower gender difference (Table 2) [139–141]. When CBD was received by inhalation or smoking, the maximal plasmatic CBD levels were in the nM range and then dropped stepwise (Table 2) [142,143].

The first trial in adult humans to compare single and multiple oral delivery was undertaken recently [144]. The single oral dose was administrated in the range of 1500–6000 mg, which is comparable to or higher than doses recommended for Epidiolex®. The maximal plasma CBD concentration, reached at 3–5 h after administration, was 292.4 ± 87.9 ng/mL (approx. 1 µM) and 782 ± 83 ng/mL (approx. 2.5 µM) for 1500 and 6000 mg, respectively, and then it dropped significantly. When CBD was administrated twice per day (2 × 1500 mg) during an extended period of 7 days, a steady-state plasma level was reached at 2 days, and on day 7, the maximal concentration was 541 ng/mL (approx. 1.7 µM).

Intravenous CBD injection is an alternative delivery method, which prevents GI degradation and has demonstrated better bioavailability. It was tested and compared with other delivery methods in studies in humans and mice (Table 2) [142,143,145]. Intravenous administration caused higher CBD plasma levels than oral administration [145], smoking [142], or inhalation [143] (Table 2). In healthy volunteers, the injection of a 20 mg/kg dose resulted in a rapid rise in the plasma concentration, ranging from 358 to 972 ng/mL (1–3 µM), which was approximately five times higher than by smoking [142]. Although these concentrations are close to the cytotoxicity range reported for some tumors (discussed in Section 2), plasma CBD levels had dropped drastically within 1 h of administration [142]. Similar results were obtained in a murine model, with an immediate plasmatic concentration rise to 3000 ng/mL.
(approx. 10 µM), when 10 mg/kg was injected, followed by a rapid (within 1 h) tenfold drop [145].

**Table 2.** Comparative studies of alternative routes of free CBD administration.

| Participants | Delivery Method | Plasma Concentration, ng/mL | Reference |
|--------------|-----------------|-----------------------------|-----------|
| Young healthy male volunteers ($n = 5$) | Smoking 20 mg | Max at 3 min: 110 ± 55 | [142] |
| | i.v. 20 mg | Max at 3 min: 686 ± 239 | | |
| | | Max at 1 h: 10.2 ± 6.6 | | |
| | | Max at 1 h: 48.4 ± 10.7 | | |
| Male ICR mice ($n = 3$) | p.o. 20 mg/kg | Max at 2 h: 111 ± 52 | [145] |
| | i.v. 10 mg/kg | Max at 10 min: 3343 ± 1048 | | |
| | | Max at 1 h: 376 ± 229 | | |
| Healthy male/female volunteers ($n = 8/8$) | p.o. 25 mg | Max at 3 h: 13.53, range: 7.9–19.1 | [139] |
| | | Max at 4 h: 2.5 | | |
| | p.o., SEDDS 25 mg | Max at 1 h: 13.53, range: 7.9–19.1 | | |
| Healthy male/female volunteers | inhalation, THC/CBD 20/20 mg | 5 min (max): 2–17 | [143] |
| | i.v., THC/CBD 10/10 mg | Max at 5 min: 14–26 | | |
| Healthy male/female volunteers | p.o., single dose 1500 mg | Max at 5 h: 292.4 ± 87.9 | [144] |
| | 3000 mg | 533.0 ± 35.1 | | |
| | 6000 mg | 782.0 ± 83.0 | | |
| | p.o., multiple dose 2 × 750 mg or 2 × 1500 mg daily | Max at 7 d: 330 | | |
| | | 541 | | |

Thus, any administration route of free CBD resulted in a transient rise in the plasmatic drug level, where only the maximal levels are comparable to cytotoxic concentrations. Importantly, bioavailability in cancer tissue is expected to be significantly lower than in plasma and highly variable, depending on the cancer type, tumor size, geometry, and vascularization. On the other hand, achieved plasma concentrations are sufficient to cause undesirable side effects (Section 6). Thus, increasing the dose of pure CBD by any administration method should not be considered as an appropriate strategy for CBD delivery for cancer treatment. Instead, alternative formulations, aimed to increase CBD’s stability and its specific targeting to the cancer tissue, should be developed.

### 7.2. Nanotechnology May Improve CBD Delivery for Cancer Therapy: General Considerations and Experimental Evidence

Multiple nanoformulations have been proposed to overcome the delivery challenges of hydrophobic unstable drugs such as CBD. There are several excellent comprehensive reviews discussing in detail the best approaches to design nanocarriers (NC) for cancer therapeutics [146–148]. There are various important criteria that should be taken into consideration. NC should be composed of biocompatible nontoxic and non-immunogenic materials. According to their chemical structure, NP can be categorized into different groups, such as inorganic, polymeric, liposomes, nanomicelles, etc. In inorganic nanoparticles, the core is composed of metal or metal oxide (silver or gold are frequently used). Polymeric NC are produced using a conjugation of several polymers with desirable char-
characteristics. Liposomes are nanoparticles with an aqueous interior part, surrounded by one or more concentric bilayers of amphipathic lipids (e.g., phospholipids). The design of such NC can be developed according to therapeutic requirements. Their diameter ranges normally from 1 nm to several µM. Consequently, such liposomes can be distributed in the bloodstream (smallest capillary diameter is approximately 5–6 µM) and accumulated in the target tumors. The ultra-filterable range of less than 200 nm provides the possibility for sterilization. Covalent linkage of NC to polyethylene glycol (PEG), so-called PEGylation, decreased significantly their immunogenicity. Moreover, such a modification changes the physicochemical and hydrodynamic properties, which results in a prolonged circulation time and reduced renal clearance [149]. NC easily incorporate drug molecules and form a barrier around therapeutic agents, preventing the premature drug interaction with body fluids and immune cells before their delivery to the target site. A precise design, which takes into consideration the material, size, and shape of NC, may provide drug release in a controlled and predictable fashion. This approach is also useful for the delivery of two or more drugs simultaneously, which can be very useful for cancer treatment, considering multi-drug chemotherapeutic protocols. Moreover, the nature of the core molecules may provide the possibility to combine both hydrophobic and hydrophilic drugs at the same time. In liposomes, hydrophobic drugs are incorporated into the lipid membrane, whereas hydrophilic compounds are present within the central aqueous cavity.

Target-specific drug delivery can significantly decrease side effects and increase the therapeutic index of encapsulated drugs. Passive and active targeting of nanoparticles can be used for cancer therapy. Passive targeting is possible due to the phenomenon known as the enhanced permeability and retention (EPR) effect in solid tumors [147,150–153]. In rapidly growing tumor tissue, characterized by the overexpression of vascular endothelial growth factor (VEGF), the microvasculature is characterized by a chaotic ramification with enhanced endothelial porosity or fenestration, in contrast to the tighter endothelial structures of normal capillaries. As a result of the changed cytoarchitecture, the blood flow is slower, and, due to the high porosity, tumor capillaries are leaky. Both these factors ensure the retention of enlarged particles, such as NC, in tumors. In hematological malignances, the bone marrow (BM) leukemic niche is the target tissue. Blood vessels supplying BM (sinusoids) possess the fenestrations and are semipermeable, providing favorable conditions for the accumulation of NC [154]. At the same time, the EPR effect was reported to provide a relatively modest, twofold enhancement of the nanodrug retention in tumor tissues, when compared with healthy organs [155].

The surface of NC can be modified to improve their targeting to tumors. A variety of ligands/antibodies to specific antigens, expressed by cancer cells, can be proposed for NC surface engineering [146]. Dual-action CXCR4-targeting liposomes were developed and proposed for drug delivery and the simultaneous blockade of the CXCR4/CXCL12 axis for leukemia treatment [156]. HER2-targeted liposomes were accumulated in the tumor tissue of patients with HER2-positive breast cancer [157]. The RGD (arginyl/glycyl/aspartic acid) motif was proposed to target integrins to tumor cells [158]. Anionic liposomes were shown to accumulate in BM and were then predominantly adsorbed by leukemic cells [154]. Hyaluronic acid, which shows a high binding affinity for the CD44 adhesion molecule, is present at enhanced concentrations in a variety of tumors and was also proposed for NC modification [159,160]. Experimental trials of novel delivery methods for CBD in cancer therapy are still scarce but have demonstrated promising results (Table 3) [161–168].

Gold PEGylated nanodrones were proposed recently to target lung cancer with cannabinoids and radiosensitizers [161]. The efficiency of two administration routes, inhalation and intravenous, was tested in transgenic mouse models bearing lung adenocarcinoma. The particle size (100 nm) was optimized to ensure an increased circulation time and efficient tumor uptake. Additionally, drones were functionalized with the RGD (arginyl/glycyl/aspartic acid) motif to target integrin receptors on the lung tumor cells’ surface. Both administration routes provided efficient nanodrone penetration into the tumor tissue, but the inhalation route was more promising for this tumor type. CBD was proposed
to be conjugated to the amine groups present on the PEG. However, CBD-conjugated drones have not been tested yet.

Table 3. Novel formulations proposed for cannabinoid delivery.

| Carrier System            | Structural Details                                      | Models Tested                                      | Administration Route | Advantages                                      | Concerns and Limitations                              | Reference |
|---------------------------|--------------------------------------------------------|----------------------------------------------------|----------------------|-------------------------------------------------|-------------------------------------------------------|-----------|
| Inorganic nanoparticles   | Gold drones loaded with CBD                            | In vivo: transgenic mouse model bearing lung adenocarcinoma | Inhalation, i.v.     | Improved: Stability Bioavailability Retention in tumors | Loading concentration Drone size for EPR              | [161]     |
|                           | Poly(styrene-co-maleic anhydride), cumene-terminated (SMA) micelles loaded with WIN | In vitro: breast cancer cell lines                 | Added to growth medium, i.v. | Improved: Stability Bioavailability Retention in tumors | Loading concentration Micelle size for EPR             | [162]     |
|                           | CBD-loaded poly-$\varepsilon$-caprolactone microparticles | In vivo: murine xenograft (glioblastoma) model      | Local delivery       | Long-lasting CBD delivery                        | Optimal particle size for better drug delivery        | [163]     |
| Polymeric microparticles  | CBD-loaded PLGA microparticles (25 µM)                | In vitro and in ovo: breast or ovarian cancer cell lines | Added to growth medium or inoculated in chicken embryos | PLGA is FDA-approved Long-lasting delivery Possibility for multi-drug co-delivery | Particle sterilization caused polymer erosion Particle size should be optimized to be suitable for bloodstream circulation | [164,165] |
| Lipid nanoparticles       | CBD-loaded and CBD-decorated (functionalized) lipid nanoparticles | In vitro: glioma cell lines                        | Added to growth medium, i.v. | Enhanced targeting and crossing of BBB Enhanced tumor targeting Biocompatible Biodegradable | Nanoparticle stability in organism                    | [166,167] |
| Proteinoid nanoparticles  | CBD-loaded Poly(RGD) proteinoid nanoparticles          | In vitro: Colon carcinoma and breast cancer Cell lines | Added to growth medium | Cancer tissue targeting                          |                                                        | [168]     |

The efficiency of a micellar delivery system for targeting cannabinoids to cancer tissue was tested in a murine model of triple-negative breast cancer [162]. In this case, micelles were loaded with the synthetic cannabinoid WIN55,212-2. The average micelle size was 152 nm, ensuring their accumulation in the tumor by the EPR. WIN, being conjugated with the micellar system, efficiently inhibited tumor growth. Remarkably, predominant micelle accumulation in the tumor was demonstrated, indicating the viability of the micellar system for its use with cannabinoids.

CBD-loaded poly-$\varepsilon$-caprolactone microparticles, as an alternative delivery system for long-term CBD administration, demonstrated their efficiency in inhibiting glioblastoma growth and tumor angiogenesis in a murine xenograft model [163].

More recently, poly-(lactic-co-glycolic acid), PLGA, microparticles, loaded with CBD, were tested for their potential to improve the conventional chemotherapy of breast and
ovarian cancers [164,165]. PLGA is approved by the FDA for use in parenteral release systems. The mean particle size was around 25 µM, with a high entrapment efficiency in the tumor tissue. Particles were sterilized by gamma irradiation (25 kGy). Since sterilization accelerates the polymer erosion, a CBD:polymer ratio (10:100) was selected to ensure a durable release profile. Remarkably, a single administration of this formulation ensures the antitumor activity in vitro for at least 10 days. CBD-loaded microparticles were effective as a monotherapy, but synergism with DEX (breast cancer) and paclitaxel (breast and ovarian cancer) allowed a more pronounced effect at a single administration. However, a particle size in the µM range is not suitable for intravenous injections, because only particles smaller than 5 µM can freely circulate in the bloodstream and reach the tumor site. Afterwards, PLGA CBD-loaded nanocarriers for i.p. administration in ovarian cancer treatment were developed, which demonstrated improved CBD stability, its long-lasting release, internalization by cancer cells, and anticancer efficiency [165].

Drug delivery to brain malignancies such as glioma/glioblastoma is restricted by the blood–brain barrier (BBB). Aparicio-Blanco and colleagues proposed the original strategy of non-immunologic BBB targeting using NC decorated (functionalized) with CBD [166,167]. They elaborated small lipid nanoparticles with a size range of 10–100 nm, carrying CBD on their surface, which were able to pass through the BBB. CBD-decorated particles were suggested to target the brain endothelium, which expresses different surface molecules able to bind CBD, namely the CB1 receptor, the G-protein-coupled receptor 55 (GPR55), and serotonin receptor 5-HT. After the brain endothelium transcytosis, these particles were expected to target glioma cells overexpressing CB1/2 receptors. As far as CBD was reported to be cytotoxic for glioma, lipid nanoparticles were loaded with CBD and tested as prolonged-release carriers for glioma therapy [166,167]. This strategy was demonstrated to enhance the glioma targeting, and a combination of CBD loading with CBD functionalization significantly reduced the IC50 values. CBD decoration was confirmed to enhance the passage of lipid nanoparticles across the BBB both in vitro (human brain endothelial hCMEC/D3 cells) and in vivo (mouse glioma xenograft models).

An RGD proteinoid polymer was synthesized and used to encapsulate CBD [168]. Resulting nanoparticles inhibited tumor growth in xenograft mouse models of colorectal and breast cancer and were proposed for further trials.

The possibility of the delivery of two or more drugs simultaneously by nanocarriers is of special interest for the inclusion of CBD into chemotherapeutic protocols, taking into the account the fact that CBD improves the effect of various anticancer drugs (Section 3). Importantly, there are several anticancer drugs that are already clinically used in liposomal formulations for chemotherapeutic protocols [169]. Among them are doxorubicin (Doxil®, 1995 and Myocet®, 2000), danourubicin (DaunoXome®, 1996), cytarabine (Depocyt®, 1999), mifamurtide (Mepact®, 2004), vincristine (Marquibo®, 2012), and irinotecan (OnivydeTM, 2015). Recently, pure CBD, encapsulated in a lipid bilayer for enhanced CBD delivery (liposomal CBD), was developed by InnoCanFarma (https://www.newsfilecorp.com/release/72614/Innocan-Pharma-Announces-Successful-Production-of-CBD-Loaded-Liposomes-under-Aseptic-Conditions, accessed on 14 February 2022).

8. Regulation Issues

Although CBD lacks any psychotropic effect, its public and clinical usage falls under general regulations applied to cannabis-derived products. Even though the difference between non-psychotropic components and THC is understood, recent circulars released by the U.S. Food and Drug Administration [170,171] strive to thoroughly evaluate the purity of cannabis products containing CBD and its derivatives and to inform the public about the risks and unknowns of these products. The current trend in several countries, including the U.S., Mexico, Canada, and Uruguay, to name those in the western hemisphere, is the decriminalization of the use of cannabis products. In 31 out of 45 European countries, CBD is legal or is within a grey legal zone (https://www.legalreader.com/cbd-in-europe-legal-status-of-cbd-country-by-country/, accessed on 10 March 2022). However, the regulations
differ from country to country and even between different states. In Mexico, in 2020, an initiative was launched to differentiate between marijuana and non-psychoactive cannabis, and respective modifications were made in the General Health Law and Federal Penal Code, approved by the Chamber of Deputies in 2021. In the case of medicinal, palliative, pharmaceutical/cosmetic, or scientific uses for said purposes, these will be regulated by the provisions of the General Health Law and other applicable regulations. The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) has publicly reiterated its “open door” policy to receive and guide all people and organizations interested in the medicinal, personal, and recreational use of cannabis. However, respective requests are attended individually and there is still a long way to go so that the requests do not necessarily have to be evaluated personally on a case-by-case basis, or by court order, but under general and clear guidelines and a regulatory framework that allows the definition of the therapeutic indications in which the use of cannabis-derived products will be prescribed, as well as the process to evaluate their quality, safety, and efficacy, in a similar way as occurs for other medicines. Therefore, researchers and clinicians who seek to employ CBD for anticancer treatments are strongly advised to consult the current status of respective regulations in their area.

9. General Conclusions and Further Considerations

The anticancer properties of CBD against cancer cells of different histogenesis were demonstrated in numerous pre-clinical in vitro studies (Section 2, Figure 1, Table A1). For many, but not all, cancer types, anticancer effects were also confirmed for animal models (Table A1, [6]). The synergic effect of CBD with conventional anticancer drugs encourages the inclusion of CBD in conventional chemotherapeutic protocols (Section 3, Table 1). The urgent need for clinical trials in developing CBD as an anticancer drug is proclaimed [6]. We provide here the suggested flowchart for the translation of the CBD anticancer activity from the lab to clinical trials and clinical use in anticancer treatments (Figure 3).

CBD acts through various molecular targets and triggers multiple signaling pathways simultaneously so that precise cytotoxic mechanism(s) for every cancer type are still to be revealed. Many studies evidenced lower, if any, cytotoxicity of CBD against healthy tissues, but the cause of the differential sensitivity of healthy and cancer tissues is still unclear. Moreover, the specific microenvironment may protect cancer cells from drug-induced damage. Thus, experiments in pre-clinical in vitro models with a high approximation of the cancer microenvironment, namely 2D and 3D co-culture with stromal cells and cancer organoids, are very desirable. The anticancer effects of CBD are often observed at relatively high concentrations of pure CBD added to cell culture or injected into animals, which can cause adverse effects, especially under long-lasting treatments (Sections 6 and 7, Tables 2 and A2). On the other hand, low CBD concentrations may even promote cancer cell proliferation [25]. Thus, new CBD formulations for targeted cancer treatments are required. NC of different design represent a promising approach for the controlled simultaneous delivery of CBD in combination with conventional chemotherapeutics. Several nanoformulations were designed and their effectiveness was proven in pre-clinical models, but this kind of study is still very scarce (Section 7, Table 3). Obviously, every new CBD formulation requires a range of pre-clinical studies in animals, which includes the evaluation of optimal administration routes, pharmacokinetics/pharmacodynamics, biodistribution, tissue and cancer cell specificity, stability, and safety. To confirm the anticancer efficacy of new formulations, cancer-specific pre-clinical models will be required, which may include chemically or genetically induced animal models, tumor allografts, and xenografts of human tumors in immunodeficient mice. Taking into consideration the high heterogeneity of cancer clones, experiments with patient-derived cancer tissue/cells are very desirable at this phase, to confirm the efficiency of CBD against specific cancer types. After satisfactorily completing all these pre-clinical studies, double-blind, randomized, placebo-controlled clinical studies could be performed. The combined use of CBD as both an antitumor and palliative agent is very attractive. Such an approach may be complicated by the fact that the effective
concentrations, formulations, and administration routes are likely to be different for these two purposes. The observed synergism of CBD with conventional anticancer drugs can decrease the efficient drug and CBD concentrations, thus optimizing the treatment (Section 3). Importantly, CBD products’ quality should be controlled and self-medication should be inhibited, to prevent inappropriate use.

Figure 3. CBD path from the bench to the bedside.

Author Contributions: Conceptualization, O.D., M.O.-A., and I.P.; investigation, L.T.-L., M.O.-A., K.V.-G., O.D., S.M.P.-T., and I.P.; writing—original draft preparation, L.T.-L., M.O.-A., K.V.-G., O.D., S.M.P.-T., and I.P.; writing—review and editing, L.T.-L., M.O.-A., K.V.-G., O.D., S.M.P.-T., and I.P.; visualization, M.O.-A., L.T.-L., and O.D.; project administration, O.D.; funding acquisition, M.O.-A. and S.M.P.-T. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the Mexican National Council of Science and Technology (CONACyT) programs (PRONACES #303072 to O.D., #302941 to S.M.P.-T.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
## Appendix A

### Table A1. Timeline of biological effects of CBD reported in different pre-clinical experimental models of cancer in vitro.

| Time  | Model                                      | Effect                  | CBD Concentration | Cellular Target Involved                  | FBS (%) | References |
|-------|--------------------------------------------|-------------------------|-------------------|-------------------------------------------|---------|------------|
| 200 s | MDA-MB-231 (breast cancer, human)          | ↑ [Ca$^{2+}$]$_i$       | EC$_{50}$ 0.7 ± 0.1 µM | N.E.                                     | 10      | [9]        |
|       | Jurkat (acute lymphoblastic leukemia, human) | ↑ [Ca$^{2+}$]$_i$       | 30 µM             | CB1 (−) CB2 (−) GPR55 (−)                 | 5       | [25]       |
| 10 min| SH-SY5Y (neuroblastoma, human)             | ↑ p-p42/44 MAPK         | 10 µM             | N.E.                                     | 10      | [44]       |
|       | Jurkat (acute lymphoblastic leukemia, human) | ↓ ΔΨm                   | 10–100 µM         | N.E.                                     | 5       | [25]       |
| 20 min| Jurkat (acute lymphoblastic leukemia, human) | Cyt-c release           | 30 µM             | N.E.                                     |         |            |
| 30 min| SH-SY5Y (neuroblastoma, human)             | ↓ p-AKT                 | 10 µM             | N.E.                                     | 10      | [44]       |
|       | EL-4 (thymoma, murine)                     | ↑ ROS                   | 16 µM             | N.E.                                     | 5       | [33]       |
|       | U87MG (glioblastoma, human)                | ↓ migration             | IC$_{50}$ 5.05 µM | CB1 (−) CB2 (−) TRPV1 (−)                 | 10      | [13]       |
| 1 h   | MDA-MB-231 (breast cancer, human)          | ↑ ROS                   | 10–25 µM          | N.E.                                     | 10      | [9]        |
|       | Jurkat (acute lymphoblastic leukemia, human) | ↑ apoptosis (sub-G0/G1) | 30 µM             | N.E.                                     | 5       | [25]       |
|       | EL-4 (thymoma, murine)                     | ↑ apoptosis (sub-G0/G1) | 16 µM             | N.E.                                     |         | [33]       |
| 2 h   | SH-SY5Y (neuroblastoma, human)             | ↑ LC3-II                | 10 µM             | CB1 (+) CB2 (+) TRPV1 (+)                 | 10      | [44]       |
| Time | Model | Effect | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|------|-------|--------|-------------------|-------------------------|---------|------------|
|      | HeLa (cervical cancer, human) | ↑ p-p38 MAPK | 10 µM | CB1 (+) | Serum-free | [39] |
|      | | ↑ p-p42/44 MAPK | 10 µM | CB2 (+) TRPV1 (+) | | |
| 2 h  | EL-4 (thymoma, murine) | ↑ ROS | 8–16 µM | N.E. | 5 | [33] |
|      | Jurkat (acute lymphoblastic leukemia, human) | ↓ migration | 10–30 µM | N.E. | | [25] |
|      | | ↑ apoptosis | 30–100 µM | N.E. | 10 | [32] |
|      | | ↑ p-mTOR | 10 µM | N.E. | | |
|      | | ↓ p-AKT | 10 µM | N.E. | | |
|      | Jurkat (acute lymphoblastic leukemia, human) | ↑ p-AKT | 5 µM | N.E. | | [22] |
|      | MDA-MB-231 (breast cancer, human) | ↓ p-AKT | 20 µM | N.E. | | [19] |
|      | T98G (glioblastoma, human) | ↓ p-AKT | 20 µM | N.E. | | [18] |
| 4 h  | U87MG, U118MG (glioblastoma, human) | ↑ p-p38 MAPK | 10 µM | N.E. | | [18] |
|      | HeLa (cervical cancer, human) | ↑ p-p42/44 MAPK | 10 µM | N.E. | Serum-free | [39] |
|      | Jurkat (acute lymphoblastic leukemia, human) | ↑ apoptosis | 30–100 µM | N.E. | 5 | [25] |
|      | | ↑ LC3-II | 30 µM | N.E. | | |
|      | Jurkat (acute lymphoblastic leukemia, human) | ↑ apoptosis | 30–100 µM | N.E. | 5 | [25] |
|      | U87MG (glioblastoma, human) | ↑ ROS | 25 µM | N.E. | Serum-free | [14] |
|      | Glioma stem-like cells (human) | ↑ ULK2 | 10 µM | N.E. | Serum-free | [16] |
|      | | ↑ BECN1 | | | | |
|      | | ↑ ATGs | | | | |
|      | | ↑ BAX | | N.E. | | |
|      | | ↑ BAD | | N.E. | | |
|      | | ↓ BCL2 | | N.E. | | |
| Time | Model | Effect | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|------|-------|--------|-------------------|--------------------------|---------|------------|
|      | MDA-MB-231 (breast cancer, human) | ↓ p-AKT | 5 µM | N.E. | 10 | [22] |
| 10 h | T98G (glioblastoma, human) | ↓ ∆Ψm | 10 µM | N.E. | 10 | [19] |
|      | U87MG (glioblastoma, human) | Cyt-c release | 25 µM | N.E. | N.E. | Serum-free | [14] |
|      | HeLa (cervical cancer, human) | ↑ p-p38 MAPK | 10 µM | N.E. | N.E. | Serum-free | [39] |
|      | Jurkat (acute lymphoblastic leukemia, human) | ↑ Caspase-9 | 30 µM | N.E. | 5 | [25] |
|      | LNCaP (prostate carcinoma, human) | ↑ Cleaved/activated Caspase-3 | 15 µM | CB1 (+) | 10 | CB2 (+) | [27] |
| 12 h | SW480 (colon carcinoma, human) | ↑ apoptosis (sub-G0/G1) | 12–16 µM | N.E. | 5 | [33] |
|      | MDA-MB-231 (breast cancer, human) | ↑ ROS | 5 µM | N.E. | 10 | [22] |
|      | LNCaP (prostate carcinoma, human) | ↑ Cleaved PARP | 15 µM | CB1 (−) | 10 | CB2 (+) | [27] |
|      | SW480 (colon carcinoma, human) | ↑ Cleaved PARP | 15 µM | CB1 (+) | 5 | CB2 (+) | [27] |
|      | Jurkat (acute lymphoblastic leukemia, human) | ↓ p-p38 MAPK | 5 µM | CB1 (−) | 10 | CB2 (+) | [31] |
| 16 h | MDA-MB-231 (breast cancer, human) | ↑ apoptosis | 7.5 µM | N.E. | 10 | [22] |
|      | T24 (bladder urothelial carcinoma, human) | ↓ migration/invasion | 32 µM | N.E. | 10 | [49] |
| Time  | Model                                      | Effect                          | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|-------|--------------------------------------------|---------------------------------|-------------------|--------------------------|---------|------------|
| 20 h  | U87MG (glioblastoma, human)                | ↑ Caspase-9                     | 25 µM             | N.E.                     | Serum-free | [14]       |
|       |                                            | ↑ Caspase-8                     |                   |                          |          |            |
|       |                                            | ↑ Caspase-3 activity            |                   |                          |          |            |
|       | MDA-MB-231 (breast cancer, human)          | ↓ invasion                      | 0.1–1.5 µM        | N.E.                     | 0.1      | [20]       |
|       | U87MG (glioblastoma, human)                | ↑ Caspase-8                     | 25 µM             | N.E.                     | Serum-free | [14]       |
|       |                                            | ↑ Caspase-3 activity            |                   |                          |          |            |
| 24 h  | U87MG, U373MG (glioblastoma, human)        |                                | 25 µM             | CB1 (−)                  |          | [12]       |
|       |                                            |                                 |                   | CB2 (+)                  |          |            |
|       |                                            |                                 |                   | TRPV1 (−)                |          |            |
|       | U87MG (glioblastoma, human)                |                                | 20–50 µM          | N.E.                     |          | [14]       |
|       | MDA-MB-231 (breast cancer, human)          |                                 | 5–10 µM           | CB1 (−)                  |          | [22]       |
|       |                                            |                                 |                   | CB2 (−)                  |          |            |
|       |                                            |                                 |                   | TRPV1 (−)                |          |            |
|       | EL-4 (thymoma, murine)                     | ↓ viability/proliferation       | 5 µM              | CB1 (−)                  |          | [31]       |
|       |                                            |                                 |                   | CB2 (+)                  |          |            |
|       |                                            |                                 |                   | TRPV1 (−)                |          |            |
|       | Jurkat (acute lymphoblastic leukemia, human)|                                 | 5 µM              | CB1 (−)                  |          | [31]       |
|       |                                            |                                 |                   | CB2 (+)                  |          |            |
|       |                                            |                                 |                   | TRPV1 (−)                |          |            |
|       | HT-29 (colorectal adenocarcinoma, human)   |                                 | 10 µM             | N.E.                     | 0.5      | [38]       |
|       | SK-N-SH (neuroblastoma, human)             |                                 | 32 µM             | N.E.                     | 10       | [43]       |
|       | Jurkat, MOLT-3, CCRF-CEM, RS4;11, Reh      |                                 | 12–50 µM          | CB2 (−)                  | 5        | [25]       |
|       | (acute lymphoblastic leukemia, human)       |                                 |                   |                          |          |            |
|       | Glioma stem-like cells (human)             |                                 | 10 µM             | CB1 (−)                  |          | [16]       |
|       |                                            |                                 |                   | CB2 (−)                  |          |            |
|       |                                            |                                 |                   | TRPV1 (−)                |          |            |
|       |                                            |                                 |                   | TRPV2 (+)                |          |            |
|       |                                            |                                 |                   | Serum-free               |          |            |
| Time  | Model                                                                 | Effect                          | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|-------|------------------------------------------------------------------------|---------------------------------|-------------------|--------------------------|---------|------------|
|       | DU-145, LNCaP (prostate cancer, human)                                 |                                 | 5–6 µM            | N.E.                     |         | [29]       |
| 24 h  | SGC-7901 (gastric cancer, human)                                        |                                 | 74 µM             | N.E.                     | 10      | [34]       |
|       | Caco-2, HCT116 (colon adenocarcinoma, human)                           | ↓ viability/proliferation       | 10 µM             | CB1 (+)                  |         | [36]       |
|       | +                      |                                 |                   | CB2 (−)                 |         |            |
|       | +                      |                                 |                   | TRPV1 (+)               |         |            |
|       | Gastric cancer cell lines (human)                                      |                                 | 6–10 µM           | N.E.                     |         | [35]       |
|       | Colorectal cancer cell lines (human)                                   | ↓ viability/proliferation       | 6–8 µM            | N.E.                     |         | [37]       |
|       | U87MG, T98G (glioblastoma, human)                                      | IC_{50} 11–13 µM               | N.E.              | Serum-free               |         | [17]       |
|       | T-47D, MDA-MB-231 (breast cancer, human)                               |                                 | 2.2–5 µM          | N.E.                     |         | [24]       |
|       | FaDu, SCC15, Hep2 (head and neck squamous cell carcinoma, human)        |                                 | 6–6.5 µM          | N.E.                     |         | [50]       |
|       | SiHa, HeLa, ME-180 (cervical cancer, human)                             |                                 | 5–10 µM           | N.E.                     |         | [42]       |
| 24 h  | SK-N-SH (neuroblastoma, human)                                          |                                 | 32 µM             | N.E.                     | 10      | [43]       |
|       | U87MG, T98G (glioblastoma, human)                                      |                                 | 1–9 µM            | N.E.                     | Serum-free | [17]       |
|       | Ishikawa, PCEM004b (endometrial cancer, human)                         | ↓ migration/invasion            | 12–25 µM          | N.E.                     | Low     | [48]       |
|       | SCC15 (head and neck squamous cell carcinoma, human)                   |                                 | 4–8 µM            | N.E.                     | 10      | [50]       |
|       | HeLa (cervical cancer, human)                                           |                                 | 10 µM             | N.E.                     | Serum-free | [39]       |
|       | SGC-7901 (gastric cancer, human)                                        |                                 | 63–127 µM         | N.E.                     | 10      | [34]       |
|       | ASPC1 (pancreatic cancer, human)                                        | (G0/G1) cell cycle arrest       | 40 µM             | N.E.                     | 10      | [47]       |
|       | Glioma stem-like cells (human)                                         |                                 | 10 µM             | N.E.                     | Serum-free | [16]       |
|       | MDA-MB-231 (breast cancer, human)                                       | ↓ Cyclin D1                     | 7.5–10 µM         | N.E.                     | 10      | [22]       |
Table A1. Cont.

| Time | Model                                      | Effect                      | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|------|--------------------------------------------|-----------------------------|-------------------|--------------------------|---------|------------|
| 24 h | T-47D, MDA-MB-231 (breast cancer, human)   |                            | 5 µM              | N.E.                     | 10      | [24]       |
|      | SGC-7901 (gastric cancer, human)           | ↓ Cyclin E                 | 31.79–127.2 µM    | N.E.                     | 10      | [34]       |
|      | U87MG (glioblastoma, human)                | ↑ necrosis (PI staining)    | 25 µM             | N.E.                     | Serum-free | [12]       |
|      | MDA-MB-231 (breast cancer, human)          | ↑ apoptosis (Annexin V)     | 5–10 µM           | N.E.                     | 10      | [22]       |
|      | Jurkat (acute lymphoblastic leukemia, human)| ↑ apoptosis (TUNEL)         | 5 µM              | CB2 (+)                  | Serum-free | [31]       |
|      | SH-SY5Y (neuroblastoma, human)             | ↑ apoptosis (sub-G0/G1)     | 50–100 µM         | N.E.                     | 10      | [44]       |
|      | SGC-7901 (gastric cancer, human)           | ↑ apoptosis–necrosis (Annexin V-PI) | 32–127 µM       | N.E.                     | 10      | [34]       |
|      | ASPC1 (pancreatic cancer, human)           |                            | 40 µM             | N.E.                     | 10      | [47]       |
|      | HL-60 (acute myeloblastic leukemia, human) | ↑ apoptosis                | 25 µM             | N.E.                     | 5       | [30]       |
|      | HCT116, DLD-1 (colorectal cancer, human)   |                            | 6 µM              | N.E.                     |         | [37]       |
|      | AGS, MKN45 (gastric cancer, human)         | ↑ apoptosis–necrosis (Annexin V-PI) | 4–10 µM        | N.E.                     | 10      | [35]       |
|      | T-47D, MDA-MB-231 (breast cancer, human)   | ↑ apoptosis                | 3–5 µM            | N.E.                     |         | [24]       |
|      | FaDu, SCC15, Hep2 (head and neck squamous cell carcinoma, human) | ↑ apoptosis–necrosis (Annexin V-PI) | 6–10 µM        | N.E.                     |         | [50]       |
|      | SiHa, HeLa, ME-180 (cervical cancer, human)| ↑ apoptosis (sub-G0/G1, Annexin V) | 10 µM           | N.E.                     | 10      | [42]       |
|      | SK-N-SH (neuroblastoma, human)             | apoptosis–necrosis (Annexin V-7AAD) | 32 µM          | N.E.                     | 10      | [43]       |
|      | MDA-MB-231 (breast cancer, human)          | ↑ Cleaved Caspase-7         | 7.5–10 µM        | N.E.                     | 10      | [22]       |
| Time | Model | Effect | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|------|-------|--------|-------------------|-------------------------|---------|------------|
| 24 h | SCC15 (head and neck squamous cell carcinoma, human) | ↑ Cleaved/activated Caspase-8 | 10 µM | N.E. | 10 | [50] |
|      | Jurkat (acute lymphoblastic leukemia, human) | | 5 µM | CB2 (+) | 10 | [31] |
|      | MDA-MB-231 (breast cancer, human) | | 7.5–10 µM | N.E. | 10 | [22] |
|      | U87MG (glioblastoma, human) | | 25 µM | N.E. | Serum-free | [14] |
|      | HCT116, DLD-1 (colorectal cancer, human) | | 6 µM | N.E. | 10 | [37] |
|      | AGS, MKN45 (gastric cancer, human) | | 4–10 µM | N.E. | 10 | [35] |
|      | SGC-7901 (gastric cancer, human) | | 32–127 µM | N.E. | 10 | [34] |
|      | MDA-MB-231 (breast cancer, human) | | 7.5–10 µM | N.E. | 10 | [22] |
|      | U87MG (glioblastoma, human) | | 25 µM | N.E. | Serum-free | [14] |
|      | HCT116, DLD-1 (colorectal cancer, human) | | 6 µM | N.E. | 10 | [37] |
|      | AGS, MKN45 (gastric cancer, human) | | 4–10 µM | N.E. | 10 | [35] |
|      | SiHa, HeLa, ME-180 (cervical cancer, human) | | 10.2 µM | N.E. | 42 | |
|      | ASPC1 (pancreatic cancer, human) | | 40 µM | N.E. | 10 | [47] |
|      | SGC-7901 (gastric cancer, human) | | 32–127 µM | N.E. | 10 | [34] |
|      | MDA-MB-231 (breast cancer, human) | | 7.5–10 µM | N.E. | 10 | [22] |
|      | HCT116, DLD-1 (colorectal cancer, human) | | 6 µM | N.E. | 10 | [37] |
|      | AGS, MKN45 (gastric cancer, human) | | 4–10 µM | N.E. | 10 | [35] |
Table A1. Cont.

| Time | Model                                      | Effect      | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|------|--------------------------------------------|-------------|-------------------|--------------------------|---------|------------|
| 24 h | MDA-MB-231 (breast cancer, human)          | ↑ t-Bid     | 7.5–10 µM         | N.E.                     |         | [22]       |
|      | AGS, MKN45 (gastric cancer, human)         |             | 4–10 µM           | N.E.                     |         | [35]       |
|      | MDA-MB-231 (breast cancer, human)          | ↑ Cleaved Beclin1 | 10 µM            | N.E.                     | 10      | [22]       |
|      | MDA-MB-231 (breast cancer, human)          |             | 10 µM             | N.E.                     |         | [22]       |
|      | SCC15 (head and neck squamous cell carcinoma, human) | ↑ Bax       |                   | N.E.                     |         | [50]       |
|      | SGC-7901 (gastric cancer, human)           |             |                   | N.E.                     |         |            |
|      | SGC-7901 (gastric cancer, human)           | ↑ Bad       | 32 µM             | N.E.                     | 10      | [34]       |
|      | MDA-MB-231 (breast cancer, human)          | ↓ Bcl-2     | 10 µM             | N.E.                     |         | [22]       |
|      | SCC15 (head and neck squamous cell carcinoma, human) | | | | | |
|      | MDA-MB-231 (breast cancer, human)          | Cyt-C release | 2.5–5 µM | CB2 (+) | 10 | [31] |
|      | Jurkat (acute lymphoblastic leukemia, human) |           |                   | CB2 (+) | 10 | [31] |
|      | SGC-7901 (gastric cancer, human)           |             | 63–127 µM         | N.E.                     |         | [34]       |
|      | MDA-MB-231 (breast cancer, human)          |             | 5–10 µM           | N.E.                     | 10      | [22]       |
|      | Jurkat (acute lymphoblastic leukemia, human) | ↑ Cleaved PARP | 2.5–5 µM | CB2 (+) | 10 | [31] |
|      | HCT116, DLD-1 (colorectal cancer, human)   |             | 6 µM              | N.E.                     | 5       | [37]       |
Table A1. Cont.

| Time | Model                                                                 | Effect            | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|------|-----------------------------------------------------------------------|-------------------|-------------------|--------------------------|---------|------------|
| 24 h | AGS, MKN45 (gastric cancer, human)                                     |                   | 4–10 µM           | N.E.                     |         | [35]       |
|      | T-47D, MDA-MB-231 (breast cancer, human)                               |                   | 3 µM              | N.E.                     |         | [24]       |
|      | SCC15 (head and neck squamous cell carcinoma, human)                   | ↑ Cleaved PARP    | 10 µM             | N.E.                     | 5       | [50]       |
|      | LNCaP (prostate carcinoma, human)                                       |                   | 15 µM             | N.E.                     |         | [27]       |
|      | SW480 (colon carcinoma, human)                                         |                   |                   | N.E.                     |         |            |
|      | Jurkat, MOLT-4 (acute lymphoblastic leukemia, human)                    | ↑ ROS             | 2.5–10 µM         | N.E.                     |         | Serum-free [31] |
|      | SGC-7901 (gastric cancer, human)                                        | ↑ mitochondrial ROS | 20 µM             | N.E.                     | 10      | [26]       |
|      | MCF-7 (breast cancer, human)                                            |                   |                   | N.E.                     |         |            |
|      | Jurkat (acute lymphoblastic leukemia, human)                           | ↓ ∆Ψm             | 2.5–5 µM          | N.E.                     | 10      | [31]       |
|      | SGC-7901 (gastric cancer, human)                                        |                   | 32 µM             | N.E.                     | 10      | [34]       |
|      | AGS (gastric cancer, human)                                             |                   | 4 µM              | N.E.                     | 10      | [35]       |
|      | MDA-MB-231 (breast cancer, human)                                       |                   | 5 µM              | N.E.                     | 10      | [22]       |
|      | Jurkat (acute lymphoblastic leukemia, human)                           | ↑ LC3-II          | 10 µM             | N.E.                     | 5       | [25]       |
|      | Glioma stem-like cells (human)                                         |                   |                   | TRPV2 (+)                | Serum-free | [16]       |
|      | SCC15 (head and neck squamous cell carcinoma, human)                   |                   |                   | N.E.                     | 10      | [50]       |
|      | Glioma stem-like cells (human)                                         |                   |                   | N.E.                     | Serum-free | [16]       |
|      | SCC15 (head and neck squamous cell carcinoma, human)                   | ↑ Beclin1         | 10 µM             | N.E.                     | 10      | [50]       |
| Time  | Model                                      | Effect                  | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|-------|--------------------------------------------|-------------------------|-------------------|--------------------------|---------|------------|
| 24 h  | MDA-MB-231 (breast cancer, human)          | ↓ p-mTOR                | 5 µM              | N.E.                     |         | [22]       |
|       | T-47D, MDA-MB-231 (breast cancer, human)  |                         | 5 µM              | N.E.                     | 10      | [24]       |
|       | MDA-MB-231 (breast cancer, human)          | ↓ p-AKT                 | 5 µM              | N.E.                     |         | [22]       |
|       | U87MG, T98G (glioblastoma, human)          | ↓ p-AKT                 | 5–9 µM            | N.E.                     | Serum-free | [17]       |
|       | U87MG, T98G (glioblastoma, human)          | ↓ p-p42/44 MAPK         | 5–9 µM            | N.E.                     |         | [17]       |
|       | AGS (gastric cancer, human)                | ↑ p-p42/44 MAPK         | 4 µM              | N.E.                     | 10 % FBS | [35]       |
| 48 h  | U87MG, U373MG (glioblastoma, human)        |                         | 25 µM (daily)     | N.E.                     | Serum-free | [12]       |
|       | FaDu, SCC15, Hep2 (head and neck squamous cell carcinoma, human) |                         | 0.1–2 µM          | N.E.                     | Serum-free | [50]       |
|       | LNCaP (prostate carcinoma, human)          | ↓ viability/proliferation | IC₅₀ 10 µM        | N.E.                     | 2.5     | [27]       |
|       | SW480 (colon carcinoma, human)             |                         | IC₅₀ 9.4 µM       | N.E.                     |         | [19]       |
|       | U87MG (glioblastoma, human)                |                         | 10 µM             | N.E.                     | 10      | [19]       |
|       | Jurkat (acute lymphoblastic leukemia, human)|                         | 30–100 µM (daily) | N.E.                     | 5       | [25]       |
|       | A549, H460, H1792 (lung cancer, human)     |                         |                   | N.E.                     | 5–10    | [41]       |
|       | A549, H460 (lung cancer, human)            |                         | IC₅₀ 14.2–15.9 µM | N.E.                     | Serum-free | [56]       |
|       | CCRF-CEM (acute lymphoblastic leukemia, human) |                         | 7.8 ± 0.2 µM      | N.E.                     | 10      | [10]       |
|       | A549, H460, H1792 (lung cancer, human)     | ↓ migration/invasion    | 30 µM             | N.E.                     | Serum-free | [41]       |
|       | HeLa (cervical cancer, human)              |                         | 10 µM             | N.E.                     | Serum-free | [39]       |
Table A1. Cont.

| Time  | Model                                                                 | Effect                          | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|-------|-----------------------------------------------------------------------|--------------------------------|-----------------------|--------------------------|---------|------------|
| 48 h  | PCEM004b, PCEM004a (endometrial cancer, human)                        | (G0/G1) cell cycle arrest       | 25–50 µM (daily)     | N.E.                     | 10      | [48]       |
|       | MCF-7 (breast cancer, human)                                          | (G1/S) cell cycle arrest        | 10 µM (daily)        | N.E.                     | 10      | [9]        |
|       | T24 (bladder urothelial carcinoma, human)                             | ↑ apoptosis-necrosis (Annexin V-PI) | 47.7 µM            | N.E.                     | 10      | [49]       |
|       | U87MG (glioblastoma, human)                                           |                                  | 20 µM               | N.E.                     | 10      | [19]       |
|       | ASPC1 (pancreatic cancer, human)                                      |                                  | 40 µM               | N.E.                     | 10      | [47]       |
|       | U87MG, U118MG (glioblastoma, human)                                   | ↑ apoptosis (sub-G0/G1)          | 5–20 µM             | CB1 (+) CB2 (+)          | 10      | [18]       |
|       | SH-SY5Y (neuroblastoma, human)                                        |                                  | 25–100 µM           | N.E.                     | 10      | [44]       |
|       | MDA-MB-231 (breast cancer, human)                                     | ↑ Caspase-3                      | 10 µM (daily)        | N.E.                     | 10      | [9]        |
|       | U87MG (glioblastoma, human)                                           | ↑ Cleaved PARP                   | 20 µM               | N.E.                     | 10      | [19]       |
|       | D425 (medulloblastoma, human)                                         | ↑ LC3-II                         | 5 µM                | N.E.                     | 1.5     | [45]       |
|       | MDA-MB-231 (breast cancer, human)                                     | ↑ p-p42/44 MAPK                  | 1.5 µM (daily)       | N.E.                     | 0.1     | [21]       |
|       | D283 (medulloblastoma, human)                                         | ↓ p-p42/44 MAPK                  | 6.5 µM              | N.E.                     | 1.5     | [45]       |
| 72 h  | FaDu, SCC15, Hep2 (head and neck squamous cell carcinoma, human)       |                                  | 0.03–0.8 µM         | N.E.                     | Serum-free | [50]     |
|       | U87MG, U373MG (glioblastoma, human)                                   |                                  | 25 µM (daily)        | N.E.                     | Serum-free | [12]     |
|       | LNCaP (prostate carcinoma, human)                                     | ↓ viability/proliferation        | IC$_{50}$ 5.95 µM   | N.E.                     | 2.5      | [27]       |
|       | SW480 (colon carcinoma, human)                                        |                                  | IC$_{50}$ 5.06µM    | N.E.                     | 2.5      | [27]       |
|       | SiHa, HeLa, ME-180 (cervical cancer, human)                            |                                  | 10 µM               | N.E.                     | Serum-free | [42]     |
| Time | Model | Effect | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|------|-------|--------|-------------------|-------------------------|---------|------------|
| 72 h | Endometrial cancer cell lines (human) | ↓ viability/proliferation | 7–45 µM (daily) | N.E. | | [48] |
|      |       |        | 19–75 µM | N.E. | 10 | [48] |
|      | U87MG (glioblastoma, human) | | 10 µM | N.E. | | [19] |
|      | D283, D425 (medulloblastoma, human) | | 3–7.5 µM | N.E. | 1.5 | [45] |
|      | IC-1425EPN, DKFZ-EP1NS (ependymoma, human) | | 8–10 µM | N.E. | 1.5 | [45] |
|      | DU-145, LNCaP (prostate cancer, human) | ↓ viability/proliferation | 25 µM | N.E. | 10 | [29] |
|      | Jurkat (acute lymphoblastic leukemia, human) | | 30–100 µM (daily) | N.E. | 5 | [25] |
|      | Jurkat (acute lymphoblastic leukemia, human) | | 10–100 µM | N.E. | 5 | [25] |
|      | | | 2.5 µM | N.E. | 1 | [32] |
|      | | | 6.4 µM | N.E. | 5 | [32] |
|      | U251 (glioblastoma, human) | | 0.6–1.2 µM | N.E. | 0.1 | [15] |
|      | MDA-MB-231 (breast cancer, human) | | 1.5 µM (daily) | N.E. | 0.1 | [21] |
|      | U87MG, T98G, HG19 (glioblastoma, human) | | 2–3 µM | N.E. | | Serum-free | [11] |
|      | U251 (glioblastoma, human) | | 0.1 µM | N.E. | 0.1 | [15] |
|      | HeLa, C33A (cervical cancer, human) | ↓ migration/invasion | 10 µM | CB1 (+) CB2 (+) TRPV1 (+) | | Serum-free | [39] |
|      | | | | CB1 (+) CB2 (+) TRPV1 (+) | | Serum-free | [40] |
|      | A549 (lung cancer, human) | | 0.1–1 µM | CB1 (+) CB2 (+) TRPV1 (+) | | Serum-free | [40] |
Table A1. Cont.

| Time   | Model                                      | Effect                          | CBD Concentration | Cellular Target Involved | FBS (%) | References |
|--------|--------------------------------------------|---------------------------------|-------------------|--------------------------|---------|------------|
| 72 h   | MDA-MB-231 (breast cancer, human)          | ↓ migration/invasion            | 1.5 µM (daily)    | N.E.                     | 0.1     | [21]       |
|        | Endometrial cancer cell lines (human)      | ↑ apoptosis (Annexin V-PI)      | 7–45 µM (daily)   | N.E.                     | 10      | [48]       |
|        | U87MG, U118MG (glioblastoma, human)        | ↑ apoptosis (sub-G0/G1)         | 5–20 µM           | CB1 (+) CB2 (+)           | 10      | [18]       |
|        | U251 (glioblastoma, human)                 | ↑ apoptosis (Annexin V-PI)      | 2 µM              | CB1 (−) CB2 (−)           | 0.1     | [15]       |
|        | U251 (glioblastoma, human)                 | (G0/G1) cell cycle arrest       | 0.4 µM            | N.E.                     | 0.1     | [15]       |
|        | Jurkat (acute lymphoblastic leukemia, human)| (G0/G1) cell cycle arrest       | 10 µM             | N.E. Serum-free           |         | [32]       |
|        | HPAFII, ASPC1 (pancreatic cancer, human)   | (G0/G1) cell cycle arrest       | 10 µM             | GPR55 (+)                 | 10      | [46]       |
|        | PCEM004b, PCEM004a (endometrial cancer, human) | ↑ LC3-II                      | 12–25 µM          | N.E.                     | 10      | [48]       |
|        | U87MG (glioblastoma, human)                |                                 | 10 µM             | N.E.                     | 10      | [19]       |
|        | U87MG, U373MG (glioblastoma, human)        |                                 | 25 µM (daily)     | N.E. Serum-free           |         | [12]       |
| 96 h   | MCF-7 (breast cancer, human)               |                                 | IC₅₀ 8.2 µM (daily)| N.E.                     |         | [12]       |
|        | MDA-MB-231 (breast cancer, human)          | ↓ viability/proliferation       | 10 µM (daily)     | CB2 (+) TRPV1 (+)         | 10      | [9]        |
|        | DU-145 (prostate cancer, human)            |                                 | IC₅₀ 20.2 µM (daily)| N.E.                     |         |           |
|        | Caco-2 (colon adenocarcinoma, human)       |                                 | IC₅₀ 7.5 µM (daily)| N.E.                     |         |           |
|        | AGS (gastric cancer, human)                |                                 | IC₅₀ 7.5 µM (daily)| N.E.                     |         |           |

N.E.: not evaluated; (−): independent; (+): dependent.
Table A2. Acute and chronic adverse effects of CBD reported in pre-clinical studies.

| Organ or System Involved | Acute Adverse Effects Reported | Species/Route/Range of CBD Dose | Chronic Adverse Effects Reported | Species/Route/Range of CBD Dose | References |
|--------------------------|--------------------------------|---------------------------------|----------------------------------|---------------------------------|------------|
| Systemic                | Organ weight elevation         | • Rat/inhaled/0.6–1.2 mg/kg     | Organ weight elevation           | Rhesus monkeys/oral/            | [112–115] |
|                         |                                | • Rhesus monkeys/intravenous/   |                                  | 30–300 mg/kg/day               |            |
|                         |                                | 150–300 mg/kg/day              |                                  |                                 |            |
|                         | Changes in THC metabolism      | Rats/subcutaneous/10 mg/kg + 10 | Decreased growth                 | Pregnant rats/oral/75–250 mg/kg/day |            |
|                         |                                | mg/kg THC                      |                                  |                                 |            |
| Cardiovascular          | Bradycardia                    | Rhesus monkeys/intravenous/150- | Decreased growth                 |                                  | [113,116] |
|                         |                                | 300 mg/kg/day                  |                                  |                                 |            |
|                         | Hypopnea                       |                                  |                                  |                                 |            |
|                         | Cardiac failure (higher doses) |                                  |                                  |                                 |            |
|                         | Hypotension                    | Piglets/intravenous/10–50 mg/kg|                                  |                                 |            |
|                         | Cardiac arrest                 |                                  |                                  |                                 |            |
| Nervous system          | Tremors                        | Rhesus monkeys/intravenous/150- | Anxiogenic-like effect           |                              |            |
|                         |                                | 300 mg/kg/day                   | Decreased brain-derived          | Rats/intraperitoneal/10 mg/kg   | [113,114,117,118] |
|                         |                                |                                  | neurotrophic factor (BDNF)       |                                 |            |
|                         | Central nervous system         |                                  | expression and related signaling |                                 |            |
|                         | inhibition                     |                                  | proteins in the hippocampus and  |                                 |            |
|                         |                                |                                  | frontal cortex                   |                                 |            |
|                         | Convulsions                    | Rats/subcutaneous/10 mg/kg + 10 | Decreased cell proliferation and  | Mice/intraperitoneal/30 mg/kg   |            |
|                         |                                | mg/kg THC                       | neurogenesis in the hippocampus   |                                 |            |
|                         |                                |                                  | and in subgranular zone          |                                 |            |
|                         | Hypolocomotion                 | Rats/subcutaneous/10 mg/kg + 10 | Neurobehavioral changes          | Pregnant rats/oral/75–250 mg/kg/day |            |
|                         |                                | mg/kg THC                       |                                  |                                 |            |
| Organ or System Involved | Acute Adverse Effects Reported | Species/Route/Range of CBD Dose | Chronic Adverse Effects Reported | Species/Route/Range of CBD Dose | References |
|--------------------------|--------------------------------|---------------------------------|---------------------------------|---------------------------------|------------|
| Reproductive system, fertility, and alterations in development and growth of the descendants | Seminiferous tubule degeneration | Rat/inhaled/0.6–1.2 mg/kg | Decreased circulating testosterone | Mice/oral/15–30 mg/kg |          |
|                          |                                |                                 | Decrease in testicular size      |                                 |           |
|                          |                                |                                 | Spermatogenesis inhibition       |                                 |           |
|                          |                                |                                 | Decrease in number of spermatozoa in the epididymis tail |                                 |           |
|                          |                                |                                 | Changes in normal cell stage in sperm formation |                                 |           |
|                          | Interference in sperm maturation | Rat/inhaled/0.6–1.2 mg/kg | Head abnormalities in sperm | Mice/oral/15–30 mg/kg |          |
|                          |                                |                                 | Cytoplasmic droplets in the flagella medial region |                                 |           |
|                          | Testicular weight decrease | Rhesus monkeys/intravenous/150–300 mg/kg/day | Increased embryofetal mortality |                                   | [112,113,119–122] |
|                          | Inhibition of spermatogenesis | Rhesus monkeys/intravenous/150–300 mg/kg/day | Developmental toxicity |                                   |           |
|                          | Dose-dependent decreased fertility of eggs and sperms | Sea urchin eggs and sperm/incubation in CBD-enriched sea water/0.1–10 µM | Decreased fetal body weight |                                   | Pregnant rats/oral/75–250 mg/kg/day |
|                          | Fertilization inhibition |                                     | Increased fetal structural variations |                                   |           |
|                          | Decrease in testosterone metabolism | Rats/intraperitoneal/10 mg/kg | Delayed sexual maturation |                                   |           |
|                          | Dose- and time-dependent acrosome reaction inhibition without reduced motility | Sea urchin sperm/incubation in CBD-enriched sea water/0.1–100 µM | Alterations in male reproductive organ development and fertility in offspring |                                   |           |
| Hepatic                  | Decrease in CYP aniline hydroxylation and p-nitroanisole demethylation | Rats/intraperitoneal/10 mg/kg | Alterations in male reproductive organ development and fertility in offspring |                                   | [121]    |
|                          | Alteration of CYP content |                                     |                                   |                                   |           |
References

1. Zuardi, A.W.; Crippa, J.A.; Hallak, J.E.; Bhattacharyya, S.; Atakan, Z.; Martin-Santos, R.; McGuire, P.K.; Guimarães, F.S. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. *Curr. Pharm. Des.* 2012, 18, 5131–5140. [CrossRef] [PubMed]

2. Massi, P.; Solinas, M.; Cinquina, V.; Parolaro, D. Cannabidiol as potential anticancer drug. *Br. J. Clin. Pharmacol.* 2012, 75, 303–312. [CrossRef] [PubMed]

3. Yeshurun, M.; Shpilberg, O.; Herscovic, C.; Shargian, L.; Dreyer, J.; Peck, A.; Israel, M.; Levy-Assaraf, M.; Gruenewald, T.; Mechoulam, R.; et al. Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: Results of a phase II Study. *Biol. Blood Marrow Transplant.* 2015, 21, 1770–1775. [CrossRef] [PubMed]

4. Christensen, A.; Pruskkowski, J. The role of cannabidiol in palliative care #370. *J. Palliat. Med.* 2019, 22, 337–338. [CrossRef] [PubMed]

5. Sunda, F.; Arowolo, A. A molecular basis for the anti-inflammation and anti-fibrosis properties of cannabidiol. *FASEB J.* 2020, 34, 14083–14092. [CrossRef]

6. Seltzer, E.S.; Watters, A.K.; MacKenzie, D., Jr.; Granat, L.M.; Zhang, D. Cannabidiol (CBD) as a promising anti-cancer drug. *Cancers* 2020, 12, 3203. [CrossRef]

7. Mangal, N.; Erridge, S.; Habib, N.; Sadanandam, A.; Reeybe, V.; Sodergren, M.H. Cannabinoids in the landscape of cancer. *J. Cancer Res. Clin. Oncol.* 2021, 147, 2507–2534. [CrossRef]

8. Most, J.; Bryk, M.; Starowicz, K. Cannabidiol for pain treatment: Focus on pharmacology and mechanism of action. *Int. J. Mol. Sci.* 2020, 21, 8870. [CrossRef]

9. Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J. Pharmacol. Exp. Ther.* 2006, 318, 1375–1387. [CrossRef]

10. Scott, K.A.; Dalgleish, A.G.; Liu, W.M. Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. *Int. J. Oncol.* 2017, 51, 369–377. [CrossRef]

11. Torres, S.; Lorente, M.; Rodriguez-Fornés, F.; Hernández-Tiedra, S.; Salazar, M.; Garcia-Taboada, E.; Barcia, J.; Guzmán, M.; Velasco, G. A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Mol. Cancer Ther.* 2011, 10, 90–103. [CrossRef]

12. Massi, P.; Vaccani, A.; Ceruti, S.; Colombo, A.; Abbacchio, M.P.; Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *J. Pharmacol. Exp. Ther.* 2004, 308, 838–845. [CrossRef]

13. Vaccani, A.; Massi, P.; Colombo, A.; Rubino, T.; Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br. J. Pharmacol.* 2005, 144, 1032–1036. [CrossRef]

14. Massi, P.; Vaccani, A.; Bianchessi, S.; Costa, B.; Macchi, P.; Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. *Cell. Mol. Life Sci.* 2006, 63, 2057–2066. [CrossRef]

15. Marcu, J.P.; Christian, R.T.; Lau, D.; Zeliinski, A.J.; Horowitz, M.P.; Lee, J.; Pakdel, A.; Allison, J.; Limbad, C.; Moore, D.H.; et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. *Mol. Cancer Ther.* 2010, 9, 180–189. [CrossRef]

16. Nabissi, M.; Morelli, M.B.; Amantini, C.; Liberati, S.; Santoni, M.; Ricci-Vitiani, L.; Pallini, R.; Santoni, G. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. *Int. J. Cancer* 2015, 137, 1855–1869. [CrossRef]

17. Solinas, M.; Massi, P.; Cinquina, V.; Valenti, M.; Bolognini, D.; Gariboldi, M.; Monti, E.; Rubino, T.; Parolaro, D. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. *PLoS ONE* 2013, 8, e76918. [CrossRef]

18. Ivanov, V.N.; Wu, J.; Hei, T.K. Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways. *Oncotarget* 2017, 8, 74068–74095. [CrossRef]

19. Ivanov, V.N.; Wu, J.; Wang, T.J.C.; Hei, T.K. Correction: Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and γ-irradiation in human glioblastoma cells. *Oncotarget* 2019, 10, 7012–7013. [CrossRef]

20. McAllister, S.D.; Christian, R.T.; Horowitz, M.P.; Garcia, A.; Desprez, P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Mol. Cancer Ther.* 2007, 6, 2921–2927. [CrossRef]

21. McAllister, S.D.; Murase, R.; Christian, R.T.; Lau, D.; Zeliinski, A.J.; Allison, J.; Almanza, C.; Pakdel, A.; Lee, J.; Limbad, C.; et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res. Treat.* 2011, 129, 37–47. [CrossRef] [PubMed]

22. Shrivastava, A.; Kuzontkoski, P.M.; Groopman, J.E.; Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol. Cancer Ther.* 2011, 10, 1161–1172. [CrossRef] [PubMed]

23. Elbaz, M.; Nasser, M.W.; Ravi, J.; Wani, N.A.; Ahirwar, D.K.; Zhao, H.; Oghumu, S.; Satoskar, A.R.; Shilo, K.; Carson, W.E., III; et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. *Mol. Oncol.* 2015, 9, 906–919. [CrossRef] [PubMed]

24. Sultan, A.S.; Marie, M.A.; Sheweita, S.A. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. *Breast Cancer* 2018, 41, 34–41. [CrossRef] [PubMed]
25. Olivas-Aguirre, M.; Torres-Lopez, L.; Valle-Reyes, J.S.; Hernandez-Cruz, A.; Pottosin, I.; Dobrovinskaya, O. Cannabidiol directly targets mitochondria and disturbs calcium homeostasis in acute lymphoblastic leukemia. Cell Death Dis. 2019, 10, 779. [CrossRef] [PubMed]

26. Mould, R.R.; Botchway, S.W.; Parkinson, J.R.C.; Thomas, E.L.; Guy, G.W.; Bell, J.D.; Nunn, A.W. Cannabidiol modulates mitochondrial redox and dynamics in MCF7 cancer cells: A study using fluorescence lifetime imaging microscopy of NAD(P)H. Front. Mol. Biosci. 2021, 8, 630107. [CrossRef]

27. Sreevalsan, S.; Joseph, S.; Jutooru, I.; Chadalapaka, G.; Safe, S.H. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res. 2011, 31, 3799–3807.

28. Piñeiro, R.; Maffucci, T.; Falasca, M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011, 30, 142–152. [CrossRef]

29. De Petrocellis, L.; Ligresti, A.; Schiano Moriello, A.; Iappelli, M.; Verde, R.; Stott, C.G.; Cristina, L.; Orlando, P.; Di Marzo, V. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms. Br. J. Pharmacol. 2013, 168, 79–102. [CrossRef]

30. Galilly, R.; Even-Chen, T.; Katzavian, G.; Lehmann, D.; Dagan, A.; Mechoulam, R. γ-irradiation enhances apoptosis induced by cannabidiol, a non-psychoactive cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk. Lymphoma 2003, 44, 1767–1773. [CrossRef]

31. McKallip, R.J.; Jia, W.; Schlomer, J.; Warren, J.W.; Nagarkatti, P.S.; Nagarkatti, M. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of the non-psychotropic cannabinoid p22phox and Nox4 expression. Mol. Pharmacol. 2006, 70, 897–908. [CrossRef]

32. Kalenderoglou, N.; Macpherson, T.; Wright, K.L. Cannabidiol reduces leukemic cell size—But is it important? Front. Pharmacol. 2017, 8, 144. [CrossRef]

33. Lee, C.Y.; Wey, S.P.; Liao, M.H.; Hsu, W.L.; Wu, H.Y.; Jan, T.R. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int. Immunopharmacol. 2008, 8, 732–740. [CrossRef]

34. Zhang, X.; Qin, Y.; Pan, Z.; Li, M.; Liu, X.; Chen, X.; Qu, G.; Zhou, L.; Xu, M.; Zheng, Q.; et al. Cannabidiol induces cell cycle arrest and cell apoptosis in human gastric cancer SGC-7901 cells. Biomolecules 2019, 9, 302. [CrossRef]

35. Jeong, S.; Jo, M.J.; Yun, H.K.; Kim, D.Y.; Kim, B.R.; Kim, J.L.; Park, S.H.; Na, Y.J.; Jeong, Y.A.; Kim, B.G.; et al. Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer. Cell Death Dis. 2019, 10, 846. [CrossRef]

36. Aviello, G.; Romano, B.; Borrelli, F.; Capasso, R.; Gallo, L.; Piscitelli, F.; Di Marzo, V.; Izzo, A.A. Chemopreventive effect of the non-psychoactive phytocannabinoid cannabidiol on experimental colon cancer. J. Mol. Med. 2012, 90, 925–934. [CrossRef]

37. Jeong, S.; Yun, H.K.; Jeong, Y.A.; Jo, M.J.; Kang, S.H.; Kim, J.L.; Kim, D.Y.; Park, S.H.; Kim, B.R.; Na, Y.J.; et al. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Lett. 2019, 447, 12–23. [CrossRef]

38. Sainz-Cort, A.; Müller-Sánchez, C.; Espel, E. Anti-proliferative and cytotoxic effect of cannabidiol on human cancer cell lines in presence of serum. BMC Res. Notes 2020, 13, 389. [CrossRef]

39. Ramer, R.; Merkord, J.; Rohde, H.; Hinz, B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of metalloproteinases-1. Biochem. Pharmacol. 2010, 79, 955–966. [CrossRef]

40. Ramer, R.; Rohde, A.; Merkord, J.; Rohde, H.; Hinz, B. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human cancer lung cells. Pharm. Res. 2010, 27, 2162–2174. [CrossRef]

41. Millan, L.; Mata, M.; Alacer, J.; Oliver, M.; Sancho-Tello, M.; de Llano, J.J.M.; Camps, C.; Galbis, J.; Carretero, J.; Carda, C. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS ONE 2020, 15, e0228909. [CrossRef] [PubMed]

42. Luheke, S.T.; Motadi, L.R. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement. Altern. Med. 2016, 16, 335. [CrossRef] [PubMed]

43. Fisher, T.; Golan, H.; Schiby, G.; PriChen, S.; Smou, R.; Moshe, I.; Peshes-Yaloz, N.; Castiel, A.; Waldman, D.; Gallily, R.; et al. In vitro and in vivo efficacy of non-psychocannabinoids in neuroblastoma. Curr. Oncol. 2016, 23, S15–S22. [CrossRef] [PubMed]

44. Vrechi, T.A.M.; Leão, A.H.F.F.; Morais, I.B.M.; Abório, V.C.; Zuardi, A.W.; Hallak, J.E.C.; Crippa, J.A.; Pinheiro, R.P.; Smaili, S.S.; et al. Cannabidiol induces autophagy via ERK1/2 activation in neural cells. Biomolecules 2019, 9, 13. [CrossRef]

45. Andradas, C.; Byrne, J.; Kuchibhotla, M.; Ancliffe, M.; Jones, A.C.; Carline, B.; Hii, H.; Truong, A.; Storer, L.C.D.; Ritzmann, T.A.; et al. Assessment of cannabidiol and A9-tetrahydrocannabinol in mouse models of medulloblastoma and ependymoma. Cancer Cell 2011, 23, 130. [CrossRef]

46. Ferro, R.; Adamska, A.; Lattanzio, R.; Mavrommati, I.; Edling, C.E.; Arifin, S.A.; Fyffe, C.A.; Sala, G.; Sacchetto, L.; Chiorino, G.; et al. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene 2018, 37, 6368–6382. [CrossRef]

47. Emhemmed, F.; Zhao, M.; Yorulmaz, S.; Steyer, D.; Leitao, C.; Alignan, M.; Cerny, M.; Paillard, A.; Delacourt, F.M.; Julien-David, D.; et al. Cannabis sativa extract induces apoptosis in human pancreatic 3D cancer models: Importance of major antioxidant molecules present therein. Molecules 2022, 27, 1214. [CrossRef]

48. Marinelli, O.; Morelli, M.B.; Annibali, D.; Aguzzi, C.; Zeppa, L.; Tuyaerts, S.; Amantini, C.; Amant, F.; Ferretti, B.; Maggi, F.; et al. The effects of cannabidiol and prognostic role of TRPV2 in human endometrial cancer. Int. J. Mol. Sci. 2020, 21, 5409. [CrossRef]
49. Anis, O.; Vinayaka, A.C.; Shaley, N.; Namdar, D.; Nadarajan, S.; Anil, S.M.; Cohen, O.; Belausov, E.; Ramon, J.; Mayzlish Gati, E.; et al. Cannabis-derived compounds cannabichromene and Δ9-tetrahydrocannabinol interact and exhibit cytotoxic activity against urothelial cell carcinoma correlated with inhibition of cell migration and cytoskeleton organization. *Molecules* 2021, 26, 465. [CrossRef]

50. Go, Y.Y.; Kim, S.R.; Kim, D.Y.; Chae, S.W.; Song, J.J. Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. *Sci. Rep.* 2020, 10, 20622. [CrossRef]

51. Sies, H.; Jones, D.P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. *Nat. Rev. Mol. Cell Biol.* 2020, 21, 363–383. [CrossRef]

52. Klionsky, D.J.; Abdel-Aziz, A.K.; Abdelfattah, S.; Abdellatif, M.; Abdoli, A.; Abel, S.; Abeliovich, H.; Abildgaard, M.H.; Abudu, Y.P.; Acevedo-Arozena, A.; et al. Guidelines for the use and reporting of assays for monitoring autophagy (4th edition). *Autophagy* 2021, 17, 1–382. [CrossRef]

53. Bergamaschi, M.M.; Queiroz, R.H.C.; Zuardi, A.W.; Crippa, J.A.S. Safety and side effects of cannabidiol, a *Cannabis sativa* constituent. *Curr. Drug Saf.* 2011, 6, 237–249. [CrossRef]

54. Rimmerman, N.; Ben-Hail, D.; Porat, Z.; Jukat, A.; Kozela, E.; Daniels, M.P.; Connelly, P.S.; Leishman, E.; Bradshaw, H.B.; Shoshan-Barmatz, V.; et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: A novel mechanism for cannabinoid-induced cell death. *Cell Death Dis.* 2013, 4, e949. [CrossRef]

55. Elbaz, M.; Ahirwar, D.; Zhang, X.; Zhou, X.; Lustberg, M.; Nasser, M.W.; Shilo, K.; Ganju, R.K. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. *OncoTargets & Therapy* 2018, 9, 33459–33470. [CrossRef]

56. Misri, S.; Kaul, K.; Mishra, S.; Charan, M.; Verma, A.K.; Barr, M.P.; Ahirwar, D.K.; Ganju, R.K. Cannabidiol inhibits tumorigenesis in cisplatin-resistant non-small cell lung cancer via TRPV2. *Cancers* 2022, 14, 1181. [CrossRef]

57. Jan, T.R.; Su, S.T.; Wu, H.Y.; Liao, M.H. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. *Int. Immunopharmacol.* 2007, 7, 773–780. [CrossRef]

58. Liu, D.Z.; Hu, C.M.; Huang, C.H.; Wey, S.P.; Wey, S.P.; Jan, T.R. Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity. *Acta Pharmacol. Sin.* 2010, 31, 1611–1617. [CrossRef]

59. Kaplan, B.L.F.; Springs, A.E.B.; Kaminski, N.E. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). *Biochem. Pharmacol.* 2008, 76, 726–737. [CrossRef]

60. Ben-Shabat, S.; Fridle, E.; Sheshkin, T.; Tamiri, T.; Rhee, M.H.; Vogel, Z.; Bisogno, T.; De Petrocellis, L.; Di Marzo, V.; Mechoulam, R. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. *Eur. J. Pharmacol.* 1998, 353, 23–31. [CrossRef]

61. Ferber, S.G.; Namdar, D.; Hen-Shoval, D.; Eger, G.; Koltai, H.; Shoval, G.; Shbiro, L.; Weller, A. The “entourage effect”: Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. *Curr. Neuropharmacol.* 2020, 18, 87–96. [CrossRef]

62. Tomko, A.M.; Whynot, E.G.; Dupré, D.J. Anti-cancer properties of cannabidiol and Δ9-tetrahydrocannabinol and potential synergistic effects with gemcitabine, cisplatin and other cannabinoids in bladder cancer. *bioRxiv* 2021. [CrossRef]

63. Fraugas-Sánchez, A.I.; Fernández-Carballedo, A.; Simancas-Herbada, R.; Martin-Sábroso, C.; Torres-Suárez, A.I. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. *Int. J. Pharm.* 2020, 574, 118916. [CrossRef]

64. Ward, S.J.; McAllister, S.D.; Kawamura, R.; Murase, R.; Neelakantan, H.; Walker, E.A. Cannabidiol inhibits paclitaxel-induced neurotoxicity induced by 5-HT1A(1A) receptors without diminishing nervous system function or chemotherapy efficacy. *Br. J. Pharmacol.* 2014, 171, 636–645. [CrossRef]

65. Nabiissi, M.; Morelli, M.B.; Santoni, M.; Santoni, G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. *Carcinogenesis* 2013, 34, 48–57. [CrossRef] [PubMed]

66. Deng, L.; Ng, L.; Ozawa, T.; Stella, N. Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. *J. Pharmacol. Exp. Ther.* 2017, 360, 215–224. [CrossRef]

67. Morelli, M.B.; Offidani, M.; Alesiante, F.; Discepoli, G.; Liberati, S.; Olivieri, A.; Santoni, M.; Santoni, G.; Leoni, P.; Nabiissi, M. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. *Int. J. Cancer* 2014, 134, 2534–2546. [CrossRef]

68. Singer, E.; Judkins, J.; Salomonis, N.; Matlaf, L.; Soteropoulos, P.; McAllister, S.; Soroceanu, L. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. *Cell Death Dis.* 2015, 6, e1601. [CrossRef]

69. Nabiissi, M.; Morelli, M.B.; Offidani, M.; Amantini, C.; Gentili, S.; Soriani, A.; Cardinali, C.; Leoni, P.; Santoni, G. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. *Oncotarget* 2016, 7, 77543–77557. [CrossRef]

70. Scott, K.A.; Dalgleish, A.G.; Liu, W.M. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. *Mol. Cancer Ther.* 2014, 13, 2955–2967. [CrossRef]

71. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships; the combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzyme Regul.* 1984, 22, 27–55. [CrossRef]
72. Olivas-Aguirre, M.; Torres-López, L.; Gómez-Sandoval, Z.; Villatoro-Gómez, K.; Pottosin, I.; Dobrovinskaya, O. Tamoxifen sensitizes acute lymphoblastic leukemia cells to cannabidiol by targeting cyclophilin-D and altering mitochondrial Ca^{2+} homeostasis. *Int. J. Mol. Sci.* **2021**, *22*, 8688. [CrossRef] [PubMed]

73. Levy, M.H.; Back, A.; Benedetti, C.; Billings, J.A.; Block, S.; Boston, B.; Bruea, E.; Dy, S.; Eberle, C.; Foley, K.M.; et al. NCCN clinical practice guidelines in oncology: Palliative care. *J. Natl. Comp. Canc. Netw.* **2009**, *7*, 436–473. [CrossRef] [PubMed]

74. Bar-Lev Schleider, L.; Mechoulam, R.; Lederman, V.; Hilou, M.; Lencovský, O.; Betzalel, O.; Sbirro, L.; Novack, V. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. *Eur. J. Intern. Med.* **2018**, *49*, 37–43. [CrossRef]

75. Highet, B.H.; Lesser, E.R.; Johnson, P.W.; Kaur, J.S. Tetrahydrocannabinol and cannabidiol use in an outpatient palliative medicine population. *Am. J. Hosp. Palliat. Care* **2020**, *37*, 589–593. [CrossRef]

76. Zenone, M.A.; Snyder, J.; Crooks, V.A. What are the informational pathways that shape people’s use of cannabidiol for medical purposes? *J. Cannabis Res.* **2021**, *3*, 13. [CrossRef]

77. Bonn-Miller, M.O.; LoBiondo, M.; Thomas, B.F.; Marcu, J.P.; Hyke, T.; Vandrey, R. Labeling accuracy of cannabidiol extracts sold online. *JAMA* **2017**, *318*, 1708–1709. [CrossRef]

78. Good, P.; Haywood, A.; Gogna, G.; Martin, J.; Yates, P.; Greer, R.; Hardy, J. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: A double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). *BMC Palliat. Care* **2019**, *18*, 110. [CrossRef]

79. Scripture, C.D.; Figg, W.D.; Sparreboom, A. Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives. *Curr. Neuropharmacol.* **2006**, *4*, 165–172. [CrossRef]

80. Hu, L.Y.; Mi, W.L.; Wu, G.C.; Wang, Y.Q.; Mao-Ying, Q.L. Prevention and treatment for chemotherapy-induced peripheral neuropathy. *Curr. Neuropharmacol.* **2019**, *17*, 184–196. [CrossRef]

81. Harris, H.M.; Gul, W.; ElSohly, M.A.; Sufka, K.J. Effects of cannabidiol and a novel cannabidiol analog against tactile allodynia in a murine model of cisplatin-induced neuropathy: Enhanced effects of sub-analgesic doses of Δ9-morphine. *Med. Cannabis Cannabinoids* **2018**, *1*, 54–59. [CrossRef]

82. Portenoy, R.K.; Ganae-Motan, E.D.; Allende, S.; Yanagihara, R.; Shaiova, L.; Weinstein, S.; McQuade, R.; Wright, S.; Fallon, M.T. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. *J. Pain* **2012**, *13*, 438–449. [CrossRef]

83. Johnson, J.R.; Burnell-Nugent, M.; Lossignol, D.; Ganae-Motan, E.D.; Potts, R.; Fallon, M.T. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. *J. Pain Symptom Manag.* **2010**, *39*, 167–179. [CrossRef]

84. Johnson, J.R.; Lossignol, D.; Burnell-Nugent, M.; Fallon, M.T. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analogies. *J. Pain Symptom Manag.* **2013**, *46*, 207–218. [CrossRef]

85. Fallon, M.T.; Albert Lux, E.; McQuade, R.; Rossetti, S.; Sanchez, R.; Sun, W.; Wright, S.; Lichtman, A.H.; Kornyeeye, E. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: Two double-blind, randomized, placebo-controlled phase 3 studies. *Br. J. Pain* **2017**, *11*, 119–133. [CrossRef]

86. Lichtman, A.H.; Lux, E.A.; McQuade, R.; Rossetti, S.; Sanchez, R.; Sun, W.; Wright, S.; Kornyeeye, E.; Fallon, M.T. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. *J. Pain Symptom Manag.* **2018**, *55*, 179–188. [CrossRef]

87. King, K.M.; Myers, A.M.; Soroka-Monzo, A.J.; Tuma, R.F.; Tallarida, R.J.; Walker, E.A.; Ward, S.J. Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. *Br. J. Pharmacol.* **2017**, *174*, 2832–2841. [CrossRef]

88. Faubel, S.; Lewis, E.C.; Reznikov, L.; Ljubanovic, D.; Hoke, T.S.; Sommer, H.; Oh, D.J.; Lu, L.; Klein, C.L.; Dinarello, C.A.; et al. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. *J. Pharmacol. Exp. Ther.* **2007**, *322*, 8–15. [CrossRef]

89. Pan, H.; Mukhopadhyay, P.; Rajesh, M.; Patel, V.; Mukhopadhyay, B.; Gao, B.; Haskó, G.; Pacher, P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. *J. Pharmacol. Exp. Ther.* **2009**, *328*, 708–714. [CrossRef]

90. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. *Kidney Int.* **2008**, *73*, 994–1007. [CrossRef] [PubMed]

91. Chatterjee, K.; Zhang, J.; Honbo, N.; Karliner, J.S. Doxorubicin cardiomyopathy. *Cardiology* **2010**, *115*, 155–162. [CrossRef] [PubMed]

92. Zhao, L.; Zhang, B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. *Sci. Rep.* **2017**, *7*, 44735. [CrossRef] [PubMed]

93. Hao, E.; Mukhopadhyay, P.; Cao, Z.; Erdélyi, K.; Holovac, E.; Liaudet, L.; Lee, W.S.; Haskó, G.; Mechoulam, R.; Pacher, P. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and gene expression. *Mol. Med.* **2015**, *21*, 38–45. [CrossRef]
120. Schuel, H.; Berkery, D.; Schuel, R.; Chang, M.C.; Zimmerman, A.M.; Zimmerman, S. Reduction of the fertilizing capacity of sea urchin sperm by cannabinoids derived from marihuana. I. Inhibition of the acrosome reaction induced by egg jelly. *Mol. Reprod. Dev.* 1991, 29, 51–59. [CrossRef]

121. Narimatsu, S.; Watanabe, K.; Matsunaga, T.; Yamamoto, I.; Imaoka, S.; Funae, Y.; Yoshimura, H. Inhibition of hepatic microsomal cytochrome P450 in cannabinoids in adult male rats. *Chem. Pharm. Bull.* 1990, 38, 1365–1368. [CrossRef]

122. Carvalho, R.K.; Santos, M.L.; Souza, M.R.; Rocha, T.L.; Guimarães, F.S.; Anselmo-Franci, J.A.; Mazaro-Costa, R. Chronic exposure to cannabinoids induces reproductive toxicity in male Swiss mice. *J. Appl. Toxicol.* 2018, 38, 1545. [CrossRef] [PubMed]

123. Iffland, K.; Grotekempen, F. An update on safety and side effects of cannabinoids: A review of clinical data and relevant animal studies. *Cannabis Cannabinoid Res.* 2017, 2, 139–154. [CrossRef] [PubMed]

124. Carvalho, R.K.; Andersen, M.I.; Mazaro-Costa, R. The effects of cannabinoids on male reproductive system: A literature review. *J. Appl. Toxicol.* 2020, 40, 132–150. [CrossRef] [PubMed]

125. Huestis, M.A.; Solimini, R.; Pichini, S.; Pacifici, R.; Carlier, J.; Busardò, F.P. Cannabidiol adverse effects and toxicity. *Curr. Neuropharmacol.* 2019, 17, 974–989. [CrossRef]

126. Cerne, K. Toxico logical properties of Δ⁹-tetrahydrocannabinol and cannabinoids. *Arch. Ind. Hyg. Toxicol.* 2020, 71, 1–11. [CrossRef] [PubMed]

127. Nelson, K.M.; Bisson, J.; Singh, G.; Graham, J.G.; Chen, S.N.; Friesen, J.B.; Dahlin, J.L.; Niemitz, M.; Walters, M.A.; Pauli, G.F. The essential medicinal chemistry of cannabinoid (CBD). *J. Med. Chem.* 2020, 63, 12137–12155. [CrossRef] [PubMed]

128. Devinsky, O.; Marsh, E.D.; Friedman, D.; Thiele, E.; Laux, L.; Sullivan, J.; Miller, I.; Flamini, R.; Willfong, A.; Filloux, F.; et al. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. *Lancet Neurol.* 2016, 15, 270–278. [CrossRef]

129. Devinsky, O.; Cross, J.H.; Laux, L.; Marsh, E.; Miller, I.; Nabbout, R.; Scheffer, I.E.; Thiele, E.A.; Wright, S.; Cannabidiol in treatment-resistant seizures in the Dravet syndrome. *N. Engl. J. Med.* 2017, 376, 2011–2020. [CrossRef]

130. Koo, C.M.; Kang, H.C. Could cannabidiol be a treatment option for intractable childhood and adolescent epilepsy? *J. Epilepsy Res.* 2017, 7, 16–20. [CrossRef]

131. Neale, M. Efficacy and safety of cannabis for treating children with refractory epilepsy. *Nurs. Child. Young People* 2017, 29, 32–37. [CrossRef]

132. Greenwich Biosciences Inc. Epidiolex [Package Insert]. U.S. Food and Drug Administration Website. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf (accessed on 11 June 2021).

133. Thiele, E.A.; Marsh, E.D.; French, J.A.; Mazurkiewicz-Beldzinska, M.; Benbadis, S.R.; Joshi, C.; Lyons, P.D.; Taylor, A.; Roberts, C.; Sommerville, K.; et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2018, 391, 1085–1096. [CrossRef]

134. Jiang, R.; Yamaori, S.; Takeda, S.; Yamamoto, I.; Watanabe, K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. *Life Sci.* 2011, 89, 165–170. [CrossRef] [PubMed]

135. Parihar, V.; Rogers, A.; Blain, A.M.; Zacharias, S.; Patterson, L.L.; Siyam, M.A.M. Reduction in tamoxifen metabolites endoxifen and N-desmethyltamoxifen (CYP3A4) with chronic administration of low-dose cannabidiol: A CYP3A4 and CYP2D6 drug interaction. *J. Pharm. Pract.* 2020, 897190020972208. [CrossRef] [PubMed]

136. Millar, S.A.; Stone, N.L.; Yates, A.S.; O’Sullivan, S.E. A systematic review on the pharmacokinetics of cannabidiol in humans. *Front. Pharmacol.* 2018, 9, 1365. [CrossRef] [PubMed]

137. Millar, S.A.; Maguire, R.F.; Yates, A.S.; O’Sullivan, S.E. Towards better delivery of cannabidiol (CBD). *Pharmaceuticals* 2020, 13, 219. [CrossRef]

138. Bruni, N.; Della Pepa, C.; Oliaro-Bosso, S.; Pessione, E.; Gaspaldì, D.; Dosio, F. Cannabinoid delivery systems for pain and inflammation treatment. *Molecules* 2018, 23, 2478. [CrossRef]

139. Knajuk, K.; Sartorius, T.; Dharsono, T.; Wacker, R.; Wilhelm, M.; Schön, C. A novel self-emulsifying drug delivery system (SEDDS) based on VESiSorb® formulation technology improving the oral bioavailability of cannabidiol in healthy subjects. *Molecules* 2019, 24, 2967. [CrossRef]

140. Cherniakov, I.; Izgolov, D.; Barasch, D.; Davidson, E.; Domb, A.J.; Hoffman, A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. *J. Control. Release* 2017, 266, 1–7. [CrossRef]

141. Atsmon, J.; Cherniakov, I.; Izgolov, D.; Hoffman, A.; Domb, A.J.; Deutsch, L.; Deutsch, F.; Heffetz, D.; Sacks, H. PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabidiol bioavailability in healthy volunteers. *J. Pharm. Sci.* 2018, 107, 1423–1429. [CrossRef]

142. Ohlsson, A.; Lindgren, J.E.; Andersson, S.; Agurell, S.; Gillespie, H.; Hollister, L.E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. *Biomed. Environ. Mass Spectrom.* 1986, 13, 77–83. [CrossRef]

143. Meyer, P.; Langos, M.; Brenneisen, R. Human pharmacokinetics and adverse effects of pulmonary and intravenous THC-CBD formulations. *Med. Cannabis Cannabinoids* 2018, 1, 36–43. [CrossRef]

144. Taylor, L.; Gidal, B.; Blakey, G.; Tayo, B.; Morrison, G.A. A phase I, Randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. *CNS Drugs* 2018, 32, 1053–1067. [CrossRef]
Pharmaceuticals 2022, 15, 366
169. Moosavian, S.A.; Bianconi, V.; Pirro, M.; Sahebkar, A. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. *Semin. Cancer Biol.* **2021**, *69*, 337–348. [CrossRef]

170. U.S. Food and Drug Administration. FDA Warns 15 Companies for Illegally Selling Various Products Containing Cannabidiol as Agency Details Safety Concerns. Available online: https://www.fda.gov/news-events/press-announcements/fda-warns-15-companies-illegally-selling-various-products-containing-cannabidiol-agency-details (accessed on 10 September 2021).

171. U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. Available online: https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process (accessed on 10 September 2021).